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ABSTRACT OF THE DISSERTATION

The Effects of a Hypocaloric Diet Enriched in Oleic Acid Using
Almonds Versus Complex Carbohydrates on Metabolic and
Anthropometric Parameters During Weight Reduction
by
Michelle Ann Wien
Doctor of Public Health in Nutrition
Loma Linda University, Loma Linda, California, 2002
Joan Sabate, Chairman

The purposes of this study were to determine the effect of almonds rich in oleic
acid as an alternative to complex carbohydrates on metabolic and anthropometric
parameters during weight reduction and to evaluate self-reported satiety and
satisfaction. A convenience sample of 57 adults was recruited from the Diabetes and
Cardiovascular Risk Reduction Program at City of Hope National Medical Center.
Subjects were randomized to an almond-enriched hypocaloric diet or to a complex
carbohydrate-enriched hypocaloric diet for twenty-four weeks. Mixed model analysis
showed that the use of almonds more favorably influenced weight loss (p< 0.0001),
body mass index (p = 0.0001), waist circumference (p = 0.0255) and fat mass (p =
0.0205) compared to complex carbohydrates. Additionally, blood ketone levels were
in

statistically significantly higher in the almond group (p = 0.0230) than in the complex
carbohydrate group. No significant difference was found in the total cholesterol:HDL
ratio between the groups, however both groups had statistically improved ratios over
time with resulting decreases in cardiovascular risk. The glucose (p = 0.0006), insulin
(p< 0.0001), insulin:glucose ratio (p = 0.0008), HgbAlc (p<0.0001), systolic blood
pressure (p = 0.0506) and diastolic blood pressure (p = 0.0371) improved in both groups
over time. Results on self-reported levels of satiety and satisfaction were unequivocal,
thus reflecting the ability of both almonds and complex carbohydrates to maintain
satiety and satisfaction in the context of medically supervised weight reduction.
Individuals participating in medically supervised weight reduction programs could be
offered almonds and perhaps other high-oleic nuts
within their prescribed weight loss diet. The potential for using almonds as a source of
oleic acid to improve the metabolic and anthropometric parameters of the obese adult
undergoing weight reduction is discussed.
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CHAPTER 1
INTRODUCTION
A. Statement of the Problem
Obesity is a chronic disease that is prevalent among adults in the United States
(US). The new obesity guidelines established by the National Institutes of Health
(NIH) led to the astounding report that 54.9 % of the US adult population is either
overweight or obese (NIH, 1998). It is well recognized that obesity contributes
significantly to both increased individual morbidity and mortality, as well as to
increased national health care costs. The NIH estimates that obesity related costs are
approaching $100 billion annually in the US (NIH, 1998).
Obesity is a strong independent risk factor for coronary heart disease. A graded
relationship appears to exist between obesity and elevated levels of atherogenic total
cholesterol and low density lipoprotein (LDL) cholesterol (Stone et ah, 1996). Mild to
moderate overweight status is associated with a substantial increased risk of type 2
diabetes mellitus, hypertension (HTN) and coronary heart disease (CHD). Obesityrelated modifiable risk factors of cardiovascular disease include metabolic syndromerelated abnormalities such as hyperinsulinemia, insulin resistance, HTN, dyslipidemia
and diminished physical activity.
Obese patients are typically advised to reduce their weight by to improve their
cardiovascular risk profile. Most weight loss methods are hopelessly ineffective and
costly. Surgical interventions for weight loss are associated with significant mortality,
hence are only advocated for the morbidly obese. Appetite suppressant medications
have a long history of risk, addiction and potential harm. However, medically
1

supervised weight reduction utilizing hypocaloric diets can be effective in facilitating
weight loss concurrent to ameliorating other cardiovascular risk factors, i.e.,
dyslipidemia and HTN, in obese adults.
Some studies have shown that weight reduction produces beneficial changes to
lipoprotein levels (Carmena, Ascaro, Tebar & Soriano, 1984; Wood et ah, 1988;
Sedgewick, Thomas, Davies & Baghurst, 1990; Cordero-Maclntyre et ah, 2000),
however others have found a deterioration in lipoprotein levels (Weinsier et al, 1992;
Phinney, Tan, Waggoner, Tezanos-Pinto & Davis, 1991). Inconsistent findings across
studies may be due to changes in variables that have an impact on lipoprotein
concentrations, i.e., energy restriction (Weinsier et al., 1992), changes in macronutrient
composition (Mattson & Grundy, 1985; Mensink & Katan, 1989; Mensink & Katan
1992), and exercise (Wood et al., 1988; Katan, 1990).
An effective weight reduction program must integrate comprehensive medical,
nutritional, exercise and behavior modification components to meet the challenges of
weight reduction and weight maintenance. The Diabetes and Cardiovascular Risk
Program (D & CVRRP) at the City of Hope (COH) National Medical Center in Duarte,
California, provides a comprehensive approach aimed at reducing obesity-associated
health risks through safe and consistent weight reduction among obese adults. However,
the conventional hypocaloric dietary intervention advocated to induce weight loss for
patients enrolled in the D & CVRRP can result in other effects that may be deleterious
to their health, i.e., a lowering of HDL-C due to the high-carbohydrate low-fat (HCLF)
macronutient composition.

2

Dietary fatty acid composition is known to influence plasma concentrations of
total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density
lipoprotein cholesterol (HDL-C) and triglycerides (Grundy & Denke, 1990) under
isocaloric conditions. Some investigators have found that no changes or even a slight
increase in HDL-C occurs when MUFA-enriched isocaloric diets are tested (Mattson &
Grundy, 1985; Mensink & Katan, 1989; Berry et ah, 1991; Baggio et ah, 1988).
Additionally, long-term compliance with a low fat diet is difficult to maintain due to
lower levels of satiety and palatability. Thus, further research is necessary to determine
the optimal macronutrient and micronutrient composition for the obese adult
undergoing medically supervised weight reduction.
B.

Purpose of the Study
The overall purpose of this study was to evaluate the effects of a complex

carbohydrate (CHO)-enriched or almond-enriched hypocaloric diet on the plasma
lipoprotein levels of obese adults during medically supervised weight reduction. The
primary study objective was to assess the effect of a HCLF hypocaloric diet enriched in
complex carbohydrate (CHO) versus a LCHF hypocaloric diet enriched with
monounsaturated fatty acids (MUFA) using almonds in obese patients enrolled in the
24-week D & CVRJRP on the following: total cholesterol (TC); high density lipoprotein
(HDL); triglycerides (TG); high density lipoprotein subfractions (HDL-C and HDLTG); low density lipoprotein subfractions (LDL-C and LDL-TG); very low density
lipoprotein subfractions (VLDL-C and VLDL-TG); and, LDL-C/HDL-C ratio. If there
is a significant difference in plasma lipoprotein levels found between the complex-CHO
enriched and the almond-enriched (MUFA) hypocaloric diets, additional studies will be
3

warranted using a high-oleic oil versus almonds to separate the effects of almonds from
those of a high fat or high MUFA diet. In the future, it would also be appropriate to
evaluate the plasma levels of lipoprotein A [Lp(a)], apolipoprotein A-I (apoA-I),
apolipoprotein B (apoB) and apolipoprotein E (apoE), however analysis of these
parameters is beyond the scope of this dissertation. Kiortsis et al. (2001) found a 7.5%
loss in body weight produced a 17.6% reduction in Lp(a) after 6 weeks of dietary
intervention in obese subjects with high pre-treatment Lp(a). The effect of the diets on
change in total body weight loss, body mass index (BMI), body composition, girth
measurements, glucose, insulin, HgbAlc, blood pressure and blood ketone levels in
study participants will also be evaluated in this dissertation. A secondary objective was
to evaluate self-reported levels of satiety and satisfaction among the study participants
during the 24-week study.
1. Importance to Nutrition
This study is important to the field of nutrition in light of the
aforementioned prevalence of obesity in the US population. The results of this study
could provide an alternative and novel approach within the field of medically
supervised weight reduction and weight management of obese adults.
C.

Research Questions
Question # 1: What are the effects of a HCLF hypocaloric diet enriched in

complex CHO versus a LCHF almond-enriched (MUFA) hypocaloric diet on the
plasma lipoprotein levels in obese adults enrolled in the medically supervised D &
CVRRP?

4

Question #2: Does the use of a LCHF almond-enriched (MUFA) hypocaloric
diet confer a beneficial effect on self-reported levels of satiety and satisfaction in obese
adults as compared to a HCLF hypocaloric diet enriched in complex CHO?
Question #3: Can the inclusion of almonds within a hypocaloric dietary regimen
be successfully used during weight loss and be sustained for a 24-week medically
supervised weight reduction program?
Question #4: Does the use of a LCHF almond-enriched (MUFA) hypocaloric
diet confer a beneficial effect on blood pressure in obese adults as compared to HCLF
hypocaloric diets enriched in complex CHO?
Question #5: What is the relationship between total body weight loss, BMI,
body composition, and girth measurements in obese adults receiving a HCLF
hypocaloric diet enriched in complex CHO versus a LCHF almond-enriched (MUFA)
hypocaloric diet?
Questions #6: Does the use of a LCHF almond-enriched (MUFA) hypocaloric
diet confer a beneficial effect on plasma glucose, insulin, HgbAlc and blood ketone
levels as compared to HCLF hypocaloric diets enriched in complex CHO?

5

CHAPTER 2
REVIEW OF LITERATURE
A.

Obesity and the Risk of Coronary Heart Disease
Epidemiological data suggest that obesity is associated with an increased risk of

coronary heart disease and that weight reduction may be beneficial to the obese
population to reduce mortality (Ashley & Kannel, 1974). A 10% reduction in relative
weight for men in the Framingham Study (Castelli et ah, 1986) resulted in a decrease in
serum cholesterol of 0.292 mmol/L, which translates into a predicted 20% decrease in
the incidence of coronary artery disease.
Obese individuals tend to have an unfavorable lipoprotein pattern, i.e., elevated
TC, LDL-C, VLDL-C, TG, apoB, and Lp(a) whereas their levels of HDL-C, apoA-I and
apoE tend to be reduced (Leenan et ah, 1993). The dangerous combination of an
elevated TC and reduced HDL-C produces an increased risk for the development of
coronary heart disease (Gordon and Rifkind, 1989). Hence, obese adults, especially
when they are hypercholesterolemic, are typically advised to reduce their weight by a
magnitude of at least 10 to 15% in order to improve their lipid profile.
Medically supervised weight reduction programs can be quite effective in
ameliorating cardiovascular risk in the obese adult. However, the standard dietary
interventions advocated for obese adults to induce weight loss can result in other effects
that may be deleterious to their health. The weight loss regimen commonly
recommended by the nutrition community is a HCLF hypocaloric diet, which may
produce a deleterious decrease in HDL-C levels (Grundy, 1986). Thus the information
compiled in this literature review addressing the substitution of dietary complex CHO
6

with a source of MUFA under hypocaloric conditions could provide additional options
for the weight reduction and weight management of obese adults.
B.

Development of Atherosclerosis
The relationship between serum cholesterol and the development of

atherosclerotic lesions has been established through the joint effort of animal research,
epidemiological studies and clinical trials. There is a wealth of circumstantial evidence
from animal studies suggesting that HDL-C is causally involved in atherosclerosis and
that reducing plasma HDL-C concentrations increases the risk of cardiovascular disease
(Katan, 1997). However, the landmark epidemiological Framingham Study revealed
the relationship between low HDL-C levels and an increased prevalence of coronary
heart disease (CHD), and, high HDL-C levels conferring protection from CHD.
Epidemiologic findings among the Mediterranean countries deserve comment.
The Seven Countries Study (Keys, 1970) showed that CHD incidence in middle-aged
men from the Mediterranean area of Southern Europe was lower than expected from
their cholesterol concentration, perhaps due to differences in nutrient intake. The
traditional Mediterranean diet features a low saturated fatty acid (SFA) content in the
background of a high total fat intake (40% to 45% of total energy) due to a high
consumption of olive oil, which is rich in MUFA, mainly oleic acid (C 18:1, n-9). The
low incidence of CHD observed in these populations may be related to the beneficial
effects of diets rich in MUFA on lipoprotein levels.
Keys, Anderson and Grande (1957) initiated pioneer work in the field of dietary
effects on serum lipids. In their classic experiment, men were studied in a mental
institution consuming isocaloric diets differing in fat content over a range of 9 to 44%
7

of calories from fat for two to nine weeks duration (usually four weeks). Sixteen
isocaloric diets were studied and yielded 41 sets of comparisons for analysis, which
produced a prediction equation for the change in serum cholesterol resulting from an
adjustment of dietary fatty acid intake. The prediction equation provided the basis for
planning safe and effective nutritional interventions to improve the health of the US
population.
C.

Serum Lipoproteins
The ideal blood lipid profile for reducing the risk of CHD is one that reflects a low

TC, low LDL-C and high HDL-C. According to the Third Report of the National
Cholesterol Education Program Expert Panel (NIH, 2001), the desirable level of TC is
less than 200 mg/dl, LDL-C less than 160 mg/dl and HDL-C greater than 40 mg/dl.
1. High Density Lipoprotein Cholesterol
Becker et al. (1983) compared the effects on plasma lipids of three
isocaloric cholesterol-free formula diets containing 40% total fat, in which the
predominant fatty acids were SFAs, MUFAs or polyunsaturated fatty acids (PUFAs).
These investigators found similar mean HDL-C levels on all three dietary interventions
after three, four-week periods using a randomized crossover design.
Shepherd et al. (1978) investigated the effects of dietary SFAs and
PUFAs on the chemical composition and thermotropic properties of HDL-C in four
healthy males during two five-week periods on a metabolic unit. Participants were fed
a 40% total fat isocaloric diet containing a P/S ratio of 0.25 and 4.0 with a five-week
washout period between study periods. These researchers found that 60% of the PUFAinduced cholesterol lowering resulted from a reduction in the atherogenic LDL-C
8

fraction, augmented by an 8% decrease in VLDL and 32% decrease in the anti
atherogenic HDL-C fraction. Analysis of the plasma HDL-C composition revealed the
percentage of cholesterol was unchanged by dietary manipulation, however PUFA
ingestion caused a significant increase in HDL phospholipid, reciprocated by a fall in
apoA-I content. Spritz and Mishkel (1969) found similar changes in LDL-C, however
not with HDL-C, as a result of PUFA-enriched isocaloric diets, and hypothesized that
because unsaturated fatty acids occupy a greater area than SFAs, they increase the space
occupied by the lipids into which they are incorporated. Catabolism of apoA-I was not
affected by increasing the PUFA level in the diet, however a decreased rate of synthesis
of apoA-I was observed. Thus, the weight of the evidence supports the theory that the
major mechanistic action of PUFAs is to alter either the production or clearance of the
plasma lipoproteins, and not to change the relative proportions of their lipid and
apoprotein components.
2. Low Density Lipoprotein Cholesterol
The literature contains conflicting reports concerning the effect of
dietary manipulation on LDL-C composition, possibly due to the variability in the
length of the intervention periods across studies. For example, Kuusi et al. (1985) noted
the LDL-C compositional changes after six weeks of a PUFA-enriched isocaloric
dietary intervention involved a decreased cholesterol and phospholipid content,
however no change in apoB content. After 12 weeks, a decrease in the apoB content
had occurred, and the composition of the LDL-C was that of baseline. Vega et al.
(1982) found a decrease of LDL apoB, yet no overall changes in the cholesterol to
protein ratio, after feeding males and females an isocaloric high fat (40%) PUFA9

enriched liquid formula diet for four weeks after being fed an isocaloric SFA-enriched
liquid formula diet in a metabolic ward setting. Bilheimer (1979) has speculated that
transient changes in the LDL-C/apoB ratio occur with changes in dietary fatty acid
intake, and may be due to delayed clearance of LDL-C, thus allowing time for greater
accumulation of cholesterol esters through the prolonged action of lecithinxholesterol
acyltransferase (LCAT).
D.

Influence of Nutrients on Serum Lipoproteins
A well-recognized non-pharmacological treatment approach to prevent or treat

non-familial CHD traditionally employs the manipulation of nutrients to fuel favorable
apolipoprotein synthesis. The quality and quantities of the macronutients consumed
will influence serum lipoprotein outcomes, thus influence CHD risk within specific
populations.
1. Saturated Fatty Acids
The major effect of the inclusion of dietary SFAs on serum lipids is
assumed to involve suppression in the activity of LDL-C receptors under isocaloric
conditions. As a consequence of a dietary intake high in SFAs, Shepherd et al. (1980)
observed a decrease in the fractional catabolic rate for LDL-C and an enhancement in
the conversion of VLDL remnants to LDL-C. This group also noted that the
hypocholesterolemic properties of PUFAs, when substituted for SFAs under isocaloric
conditions appear to be the result of increased activity of LDL-C receptors. Available
evidence suggests that the effects of PUFAs may be passive, i.e., the suppression of
activity by SFAs is removed and the LDL-C receptors return to their normal activity
(Grundy & Denke, 1990). On the basis of current knowledge, a similar passive effect
10

probably also exists for MUFAs as a substitute for SFAs in the background of an
isocaloric diet.
2. Carbohydrates Versus Monounsaturated Fatty Acids
HCLF dietary profiles have been historically recommended for the
prevention of CHD. Based on the equations of Keys, Anderson and Grande (1957) and
Hegsted (1965), it was accepted for over two decades that dietary MUFAs (i.e., oleic
acid) have no effect on serum cholesterol under isocaloric conditions. However, since
1985 there have been investigators who have challenged this conclusion, concurrent
with the advent of improved study designs. To investigate the putative
hypocholesterolemic effect of dietary MUFAs, the SFAs and PUFAs have to be held
constant. In many prior investigations, MUFAs were substituted for either SFAs or
PUFAs under isocaloric conditions. However, because both SFAs and PUFAs affect
plasma lipid concentrations in opposing directions, the role of MUFAs could not be
defined precisely.
Grundy (1986) and Mensink and Katan (1987) observed that in contrast
to MUFAs, dietary CHO reduces HDL-C levels when exchanged for dietary SFAs in
the traditional isocaloric Western diet. Mensink et al. (1989) explored the effects of a
LCHF MUFA-enriched diet using oleic acid-rich olive oil versus a HCLF diet enriched
in complex CHO diet on apolipoproteins and subfractions of HDL-C under isocaloric
conditions within an outpatient adult population for five weeks using a parallel study
design. Solid food meals were prepared in a metabolic kitchen and supplied to the
study participants. Both dietary interventions reduced LDL-C to the same extent and in
agreement with the results of Grundy (1986). Prior to this study, Grundy had received
11

criticism for using liquid formula diets to compare a high-SFA diet versus a highMUFA (high oleic safflower oil) diet versus a high glucose diet for three four-week
periods under metabolic ward conditions. Thus, the research community adopted the
belief that the observed lipid lowering effects of MUFAs on LDL-C are probably due to
dietary oleic acid rather than to some unknown factor in olive or safflower oil.
Numerous subsequent studies have supported the findings of Grundy
(1986) and Mensink et al. (1987), i.e., an isocaloric HCLF diet induces a decrease in
TC, LDL-C and HDL-C, with a concomitant increase in VLDL-TG, in contrast to an
isocaloric LCHF MUFA-enriched diet which reduces TC, LDL-C, and VLDL-TG with
little or no effect on HDL-C (Baggio et al., 1988; Garg, Bonanome, Grundy, Zhang, &
Unger, 1988; Ginsberg et al., 1990; Berry et al., 1992). The magnitude of the response
to dietary MUFAs in these aforementioned studies is variable, which Berry et al. (1992)
suggests may be modulated by the macronutrient composition of the preceding
isocaloric diet consumed by the study participants. However, the experimental design
and duration of the studies also differ. Additionally, investigators employ different
kinds of participants (e.g., students, prison inmates, patients in mental institutions,
hyperlipidemic patients, and patients with diabetes mellitus) of variable ages and
subject them to different kinds of diets, i.e., liquid formula versus solid meals. Studies
reported in the literature might be performed in metabolic units or in free-living settings
with meals provided to participants.
The metabolic unit studies involving HCLF versus LCHF (MUFAenriched) dietary interventions have featured crossover designs under isocaloric
conditions, with or without randomization, small sample sizes (approximately n = 10),
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and predominantly males. Length of time exposed to the metabolic ward dietary
interventions has ranged from three to six weeks, whereas studies in free-living settings
have been typically ten weeks in duration per dietary intervention period. These studies
have utilized a level of fat in the high-MUFA dietary interventions ranging from 33 to
50% of total calories, with a fatty acid profile ranging between 4-10% SFA, 17-33%
MUFA, and 5-11% PUFA, and a level of fat on the high-CHO diets ranging from 1831%. Additionally, Yu, Derr, Etherton and Kris-Etherton (1995) noted the neutral
response to MUFAs previously reported by investigators could be due to the variable
amount of cholesterol in the experimental diets.
Hopkins and Barter (1986) suggest an explanation for the dietary CHO
induced fall in HDL-C under isocaloric conditions. These investigators noted a rise in
hepatic secretion of VLDL-TG, as observed on isocaloric HCLF diets, and fractional
catabolism of plasma apoA-I.
The mechanism by which isocaloric LCHF (MUFA-enriched) diets
reduce LDL-C is not clear. Berry et al. (1992) noted the LDL-receptor activity of
circulating monocytes at the end of a LCHF (MUFA-enriched) diet using olive oil and
100 g almonds/d was approximately 20% higher than at the end of a HCLF dietary
intervention under isocaloric conditions. This difference in LDL-receptor activity could
have caused accelerated LDL-C clearance from the circulation and thus a lower plasma
LDL-C concentration.
Mensink and Katan (1992) evaluated 27 controlled trials published
between 1970 and 1991 using meta-analysis and found that the replacement of dietary
CHO with cis-MUFA or PUFA fat sources lowered serum TG under isocaloric
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conditions, independent of the nature of the fat. These investigators also found that the
replacement of dietary SFAs by unsaturated fatty acids typically raises the HDL-C to
LDL-C ratio, whereas replacement by dietary CHO has no effect on increasing HDL-C.
However, caution must be exerted with extrapolation of this data to free-living
populations because if high fat diets promote obesity, then their favorable effects on
serum lipids will be lost.
3. Polyunsaturated Fatty Acids Versus Monounsaturated Fatty Acids
Mattson and Grundy (1985) found smaller decreases in HDL-C using an
isocaloric 40% total fat formula diet with 28% MUFAs, as compared to PUFAs, using
participants within a metabolic unit setting with four-week dietary interventions.
Mensink and Katan (1989) subsequently compared the effects of an isocaloric diet
enriched with MUFAs or PUFAs on levels of LDL-C and HDL-C in healthy adults for a
five-week duration using a randomized parallel study design. The PUFA-enriched
dietary intervention did not reduce the levels of HDL-C or apoA-I, in contrast to the
findings of Mattson and Grundy (1985). These investigators noted that previous studies
that demonstrated a decline in the HDL-C level featured very high P/S ratios (2.0 to 6.5)
and/or other changes in the dietary intervention, i.e., an increase in CHO, a decrease in
cholesterol, or both. Hence it is possibly immaterial whether dietary SFAs are replaced
by a mix of MUFA and PUFA, or by PUFA alone, in the isocaloric Western diet; both
will have the same effect on the HDL-C as long as extremely large amounts of PUFAs
(13% of energy) are avoided.
Wahrburg, Martin, Sandkamp, Schulte, & Assmann (1992) used a
crossover study design to investigate the effects of the American Heart Association
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(AHA) Step 1 diet versus a MUFA- enriched diet (with equivalent total fat under
isocaloric conditions) after a change from the high SFA intake characteristic of the
Western diet. Serum TC and LDL-C values were reduced with equal efficacy, however
significant reductions in HDL-C were found on both the Step 1 and MUFA-enriched
dietary interventions. Mensink and Katan (1987) observed only slight decreases in
HDL-C concentrations on their high fat (40%) isocaloric diets with moderate amounts
of PUFA (12% of energy) or MUFA (15% of energy).
Using a randomized blind crossover study design, Wardlaw and Snook
(1990) compared serum lipid and apolipoprotein concentrations in 20 men consuming
40% of energy as fat from isocaloric diets based on corn oil, high-oleic sunflower oil,
and butter. Each phase of the crossover design included two weeks of a butter-based
dietary intervention followed by five weeks of the designated vegetable oil intervention
with a seven-week washout period between phases. The vegetable oil intervention
reduced serum TC by 16-21%, LDL-C by 16-21%, TG by 10-21%, and apoB by 2229% without a concurrent change in serum HDL-C or apoA-I levels. Thus even an
isocaloric diet containing 40% energy from fat can allow for a substantial reduction in
blood lipids if the intake of SFAs is minimized. In a subsequent study, the same group
examined the effects of PUFA or MUFA -enriched (canola oil )isocaloric diets, each
with 40% total fat, compared with a SFA-enriched isocaloric diet under closely
supervised feeding conditions using a randomized parallel design among male
volunteers (Wardlaw, Snook, Lin, Puangco, & Kwon, 1991). Replacing much of the
dietary SFA with either MUFA or PUFA reduced serum LDL-C levels by > 10-20%,
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with a trend towards larger and more consistent changes in LDL-C on the PUFA
intervention. However, HDL-C remained almost neutral on both interventions.
Berry et al. (1991) evaluated the effects of a MUFA-enriched diet using
almonds versus a PUFA-enriched diet using walnuts under isocaloric conditions in a
randomized crossover design featuring 12-week study periods in free-living male
students. Adherence to the dietary interventions was monitored by changes in
erythrocyte membrane composition, thus strengthening the validity of the results. High
PUFA versus high MUFA intake resulted in a somewhat lower reduction in TC (16%
versus 10%), however HDL-C remained neutral on both dietary interventions. Further
investigations are warranted using free-living females and for determination of whether
serum lipid concentrations would be maintained or drift back to the initial values over a
longer time period.
Sirtori et al. (1986) utilized a randomized crossover study design to
evaluate the activity of isocaloric low-fat (30% of total calories) diets using olive oil or
com oil on semm lipids and platelets in 23 subjects with high atherosclerotic risk
factors over an eight week time period. Plasma TC was reduced with com oil, however
HDL-C levels fell lower with corn oil and were unchanged, or raised, by olive oil.
Plasma apoB levels were reduced equally by both dietary interventions, and both the
apoA-I and the apoA-I/apoB ratio rose only with the olive oil. Platelet studies
performed provided evidence that the two interventions exerted similar favorable
effects.
Yu, Derr, Etherton, and Kris-Etherton (1995) performed a meta-analysis
of controlled feeding studies published between 1970 and 1993 in which the effects of
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dietary fatty acid manipulations on plasma lipids and lipoproteins were reported. Their
study suggests that MUFA-enriched isocaloric diets significantly decrease serum TC
and LDL-C, and increase HDL-C concentrations in both men and women. These
investigators speculate that the magnitude of the effect of MUFAs is dependent on the
amount of SFAs (and specifically the amount of hypercholesterolemic SFA, i.e. 12:016:0 SFAs) in the dietary intervention.
An alternative substitution for dietary PUFA and MUFA containing oils
is the inclusion of avocado. Colquhoun, Moores, Somerset and Humphries (1992)
conducted a randomized crossover trial to compare a high MUFA diet enriched with
avocado with an AHA Step 3 diet (low fat high-complex-CHO) in females (n=15) with
three three-week dietary intervention periods under isocaloric conditions. The avocado
intervention was more effective in lowering TC, LDL-C and apoB, and had no
deleterious effects on HDL-C or apoA-I levels. The investigators noted that avocado
contains no squalene, which is found in appreciable amounts in olive oil. These
investigators also reported an easy adjustment by participants to an avocado-enriched
dietary intake, i.e., avocado was reportedly easier to tolerate by study participants than
the high-complex CHO dietary intervention.
Lichtenstein et al. (1993) compared a typical Western dietary intake with
the use of canola, com and olive oils incorporated into a National Cholesterol Education
Program Step 2 dietary intervention in female and male participants for four 32-day
study phases under isocaloric conditions. None of the oils providing 20% of the total
calories offered a significant advantage against each other, however a 15% reduction in
LDL-C resulted in comparison to the Western diet.
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Epidemiological evidence supports the known safety of isocaloric
MUFA-enriched diets, which are advantageous with respect to preserving apoA-I
levels. Since there are no known adverse effects under isocaloric conditions, an increase
in the intake of MUFAs as a replacement for dietary SFAs may be generally
recommended to the public. Additionally, the use of MUFA-rich foods increases the
variety in meal planning and may improve long-term compliance in TC and LDL-C
lowering dietary interventions.
4.

Energy Restriction and Serum Lipids
Several investigators have studied the effects on serum lipids of weight

loss by energy restriction. The sequential effects of an isocaloric AHA Step 1 diet for a
two month period and subsequent hypocaloric AHA Step 1 diet for six months was
evaluated in 48 normocholesterolemic and hypercholesterolemic obese postmenopausal
women who were free of comorbid diseases (Nicklas, Katzel, Bunyard, Dennis, &
Goldberg, 1997). The use of a sequential study design permitted the independent
analysis of the relative contribution of dietary change and weight reduction to changes
in serum lipids. The hypocaloric AHA Step 1 diet reduced HDL-C levels in all women,
with the largest decreases occurring in women with the highest baseline HDL-C
concentrations. Weight loss partially corrected this decline, however a net decrease in
HDL-C levels was observed in these women. These findings are analogous to the
findings of Leenen et al. (1993) who observed the effects of a low-fat isocaloric diet and
weight loss to be additive on reducing TC, whereas the HDL-C lowering effect of the
isocaloric low-fat diet was counteracted by the weight loss which induced an increase in
the HDL-C among the middle-aged obese men and women.
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The clinical importance of the aforementioned study (Nicklas et ah,
1997) is found in noting the differential lipid responses to the isocaloric AHA Step 1
diet and weight loss which result on the basis of the participant’s baseline lipid
concentrations. Women with hypercholesterolemia had significant decreases in TC,
LDL-C and TG, however no significant lipid changes occurred among
normocholesterolemic or mildly hypercholesterolemic women. A major study
limitation was that the women were still significantly overweight at the completion of
the six-month weight loss phase. Also, the effects on lipoproteins of weight loss alone
cannot be assessed, i.e., weight loss without a low-fat isocaloric diet may increase
HDL-C above baseline levels while also lowering TC, LDL-C and TG. Lastly, the
effects of the intervention on other coronary artery disease risk factors, i.e., glucose
tolerance, fibrinolysis and blood pressure, were not examined.
Weinsier et al. (1992) observed that TC, LDL-C, and TG were reduced
independently by both energy restriction and weight loss utilizing a four phase study
design to separate the effects of energy restriction and weight loss on lipid and insulin
concentrations of 24 obese postmenopausal women. The hypocaloric diet provided
contained 55% CHO, 22% fat, and 23% protein with a P/S ratio of 0.7. The energyrestriction effect was determined by comparing average values in stable-weight phases
(I and IV) with low-energy phases (II and III) and demonstrated lower levels of TG,
TC, LDL-C and LDL-C/HDL-C ratio, and an increased HDL-C. The weight loss effect
was determined by comparing values in obese phases I and II with reduced weight
phases III and IV, with resulting reductions in TG, TC and LDL-C without a change in
the HDL-C or LDL-C/HDL-C ratio. These findings suggest that reducing to a weight19

steady nonobese state significantly lowers TG, TC, and LDL-C but does not improve
HDL-C or the LDL-C/HDL-C ratio using a hypocaloric HCLF dietary regimen.
These studies reflect the nutritional dilemma which exists in the
treatment of obesity, i.e., a decline in HDL-C concentration in response to a HCLF diet
is potentially harmful for older women who are at a heightened risk for coronary artery
disease (CAD). This adverse effect may be nullified by the concomitant reduction in
the concentration of the atherogenic LDL-C. However, only women with elevated
baseline LDL-C levels are likely to show significant decreases in their LDL-C and their
LDL-C/HDL-C ratio. Thus, an isocaloric HCLF without substantial weight loss may
not be beneficial for improving lipoprotein lipid risk factors in obese, postmenopausal
women with normal lipid profiles.
Zambon et al. (1999) studied the effects of a CHO-enriched versus an
olive oil-enriched (MUFA) hypocaloric diet on plasma lipoprotein levels in 20 mildly
obese premenopausal women. Both diets were effective in reducing body weight,
however at steady weight conditions, only the high MUFA diet improved LDL-C and
HDL-C subclasses. HDL-C increased significantly in the high-MUFA group, whereas a
decreased level was observed in the high CHO group. Future studies should evaluate
changes in lipids and lipoproteins in participants who lose comparable amounts of
weight, but do so by adhering to diets that differ significantly in their macronutrient
content and using whole foods.
Dattillo and Kris-Etherton (1992) quantified the effects of weight loss by
dieting on lipids and lipoproteins by performing a meta-analysis of 70 studies from
1966 to 1989. Results indicated that weight reduction was associated with significant
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decreases and correlations for TC (r = 0.32), LDL-C (r = 0.29), VLDL-C (r = 0.38) and
TG (r = 0.32). For every kilogram decrease in body weight, a 0.009 mmol/L increase
in HDL-C concentration occurred for participants at a stabilized reduced weight, and a
0.007 mmol/L decrease for participants actively losing weight. Thus, one may conclude
that weight reduction, when maintained, has beneficial effects on the lipid profile of
obese individuals.
Gumbiner, Low, and Reaven (1998) utilized a randomized parallel group
design to determine whether the lipoprotein response to weight loss in obese male and
female subjects with type 2 diabetes could be improved by using a MUFA-enriched
hypocaloric formula [10% CHO, 70%FAT, 20% protein (PRO)] as compared to the
commonly prescribed low-fat high-CHO hypocaloric diet (70% CHO, 10% FAT, 20%
PRO) for a six-week period. Both diets produced decreases in TC, LDL-C, HDL-C,
TG, and apoA-I and apoB. However, the MUFA-enriched group manifested a greater
decrease in TC, TG, and apoB and a smaller decrease in HDL-C and apoA-I than the
high-CHO group. Hence this study demonstrated that macronutrient composition of
hypocaloric diets is an important determinant of the lipoprotein profile in a type 2
diabetic population. Since the sample size in the two groups was small, i.e., eight
participants in the high-CHO group and nine participants in the MUFA-enriched group,
additional studies are warranted with observations of longer duration to allow for a
more complete assessment of MUFA-enriched hypocaloric diets.
Research on the effects of dieting on serum lipids performed among
females is scant, and the literature search dwindles further when looking at studies
involving obese females. Studies designed to solely involve this homogeneous study
21

population limit generalization of the findings, however the increasing prevalence of
obesity among US women deserves heightened attention to their inclusion into future
clinical trials.
E.

Protective Effect of Nuts on Cardiovascular Risk Factors
Nuts possess several known nutrients that are postulated to provide a protective

effect against coronary heart disease (Sabate & Fraser, 1993). Recent epidemiological
research findings from Mediterranean countries and the Adventist Health Study have
stimulated an interest in evaluating nuts and in promoting novel methods of
incorporating the frequent consumption of nuts into the US mainstream (Fraser, Sabate,
Beeson, & Strahan, 1992). Berry et al. (1991) inadvertently were the pioneers of nut
research with their initial Jerusalem Nutrition Study that evaluated the benefits of a
high-PUFA versus high-MUFA dietary intervention in male students under isocaloric
conditions. However, Abbey et al. (1994) was the first group to directly compare the
effects of nuts of different fatty acid compositions on plasma lipids. Using a nine-week
supplemental field study design with 16 normolipidemic males, participants consumed a
background diet with 18% of calories from fat in combination with an additional 18%
fat being provided during three three-week periods to create either a Western dietary
profile, a MUFA-enriched (86g/d of raw almonds) profile, and lastly a PUFA-enriched
(68 g/d of raw walnuts) profile under isocaloric conditions. Almond supplementation
produced significant reductions in TC and LDL-C, 7% and 10%, respectively, and
walnut supplementation yielded 5% and 9% reductions respectively. This group
commented that almonds may confer an advantage over walnuts in lowering cholesterol
and in reducing the risk of coronary heart disease in that they (Abbey, Noakes, Beling,
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& Nestel, 1993) and others (Berry et ah, 1991; Reaven et al., 1991) have demonstrated
that LDL-C from participants consuming diets rich in PUFAs is more prone to
oxidation than is LDL-C from participants consuming MUFA-enriched diets under
isocaloric conditions.
Spiller et al. (1990) compared the plasma cholesterol lowering properties of
almonds (lOOg/d) and olive oil against a control group under isocaloric conditions using
hypercholesterolemic males and females for a four-week period using a parallel group
study design. Compared to the control group, both the almond and the olive oil dietary
interventions caused a reduction in TC with no change in HDL-C and TG. These
investigators speculated that the greater effect on the TC found in the almond group
may be due to the different dietary P/S ratios (almond = 3.5; 0.47 = olive oil), the
vegetable protein of the almond (Kritchevsky et al., 1981), or the fiber within the
almond (Brown, Rosner, Willett, & Sacks, 1999).
Sabate et al. (1993) compared the effects on serum lipids of a diet rich in
walnuts (20% of total calories) to a control diet (AHA Step 1) under isocaloric
conditions using a controlled, randomized crossover design in 18 normocholesterolemic
males over two four-week periods. Reduced lipid levels were seen on both dietary
interventions, however the walnut-enriched diet further decreased TC and LDL-C by
12% (22.4 mg/dl) and 16% (18.2 mg/dl) respectively. A 2.3 mg/dl reduction in HDL-C
was observed in the walnut-enriched diet, however a significant decrease in the LDLC/HDL-C ratio occurred.
The inclusion of 60 to 120 g/d of raw almonds, cashews and peanuts into a
vegetarian isocaloric diet was explored to determine the effect on serum lipids in ten
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healthy male and female participants using a randomized crossover design (control diet
= 30% fat) and produced significant improvements in the serum lipid profile after 2
weeks (Jenkins et ah, 1997). However one is unable to separate the effects of the nuts
versus the vegetables from the study design.
O'Byme, Knauft and Shireman (1997) studied post-menopausal
hypercholesterolemic women who were previously consuming a 34% fat diet and
placed them onto an isocaloric low-fat (26% fat) MUFA-enriched diet incorporating
high-oleic peanuts for a 6-month period. Women already consuming low-fat isocaloric
diets were used as controls to monitor the variation in serum lipids due to seasonal
variations. Serum TC and LDL-C levels decreased 10% and 12% respectively in the
peanut intervention. Additionally, the peanut intervention showed a trend toward
beneficial changes in the LDL-C/HDL-C and apoA-I/apoB ratios as compared to the
control group.
Rajaram, Burke, Connell, Myint and Sabate (2001) recently investigated the
effects of a 20% isoenergetic replacement of an AHA Step I diet using pecans rich in
monounsaturated fat in adults with normal to moderately high serum cholesterol. This
single-blind, randomized, controlled, crossover feeding study found that the pecanenriched diet decreased serum TC and LDL-C by 6.7 and 10.4%, respectively and TG
by 11.1% beyond the Step I diet, while increasing HDL-C by 2.5 mg/dl. Thus the
weight of evidence may be considered in favor of the use of nuts to reduce the
prevalence of dyslipidemia among obese adults.
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F.

Satiation and Satiety
Both satiation and satiety can be defined by measurable events. Satiation

develops during the course of a meal and eventually brings the meal period to an end
(Blundell, Lawton, Cotton, & Macdiarmid, 1996). Satiety is the state in which further
eating is inhibited and follows the end of an eating episode, i.e., arises as a consequence
of food ingestion. The intensity of satiety is measured by the duration of time that
elapses until eating is recommenced, or by the amount consumed at the next meal
(Blundell et al., 1996).
The regulation of food intake involves the complex processes of hunger, appetite
and satiation. The presence of physiologic hunger initiates food-seeking behavior,
however the sensation of hunger may be modified by many factors, including the
cephalic phase of appetite, which is the response to the thought, sight, taste, or smell of
food (Anderson, 1996). Appetite, the desire for food, may lead to the specific intake of
energy to satisfy body energy deficits, specific nutrient requirements, or to meet a
hedonic desire for a specific taste (Anderson, 1996).
Upon food ingestion, complex physiological and psychological responses occur
which lead to satiation and the termination of food intake. Under hypocaloric
conditions, hunger sensations can be decreased by the intake of energy containing
macronutrients or by meeting one’s nutrient specific appetite. Dietary bulk,
macronutrient composition, rate of absorption, and metabolic responses affect the time
frame in which satiety ultimately occurs. The duration of satiety and the interval to the
next ingestion of food depend on a complex system of neuronal responses integrated in
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the central nervous system (Anderson, 1996). Additionally, the presence of others
eating, social factors and hedonic factors contribute to the relative state of satiation.
1. Leptin
Obesity is positively correlated with increased leptin levels, insulin
resistance, dyslipoproteinemia, and hypercoagulability. Adipocytes secrete leptin, a
protein molecule with a secondary cytokine structure whose concentrations correlate
with the amount of adipose tissue. Increased leptin levels downregulate appetite and
increase sympathetic activity and thermogenesis in the hypothalamus (Haynes, Morgan,
Walsh, Mark, & Sivitz, 1997). One mechanism through which leptin acts in regulating
food intake is inhibition of the synthesis and release by the hypothalamus of
neuropeptide-Y (NPY) (Stephens et al., 1995). Diet-induced weight loss reduces
adipose TNF-alpha expression and serum leptin levels and is associated with improved
insulin sensitivity and lipid metabolism.
Havel, Townsend, Chaump and Teff (1999) found high-fat meals
reduced 24-hour circulating leptin concentrations in normal weight women under
isocaloric diet conditions. These investigators previously reported that adipocyte
glucose utilization is involved in insulin-induced leptin secretion in vitro. However,
there is a nocturnal increase of leptin that is related to the insulin response to meals.
Theoretically, LCHF meals, which induce smaller insulin and glucose responses, would
produce lower leptin concentrations than HCLF meals. Consumption of LCHF meals
resulted in lowered 24- hour circulating leptin concentrations, which the authors suggest
may be a consequence of decreased adipocyte glucose metabolism.
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2.

Influence of Macronutrients
There is agreement among researchers that protein is the most satiating

of all the macronutrients (Hill & Blundell, 1986; Rolls, Heatherington, & Burley, 1988).
Calorie for calorie, amino acids contribute more than carbohydrate and fat to the
suppression of hunger in the post-absorptive period (Booth & Chase, 1970). Thus there
may be a direct effect of protein, or of its amino acid content in regulating satiety
(Anderson, Li, & Glanville, 1984). Animal studies and human studies have found that
protein ingestion leads to less food intake in the next meal than can be accounted for by
protein energy content alone (Li, 1982; Barkeling, Rossner, & Bjorvell, 1990).
There is controversy about how fat affects hunger, satiety and the
regulation of food intake. High fat intakes may contribute to the process of satiation
through a variety of mechanisms. Specific brain neuropeptides (e.g., galanin) are
proposed to regulate fat intake (Akabayashi et al, 1994), and fat ingestion leads to the
release of cholecystokinin, which slows gastric emptying and provides a direct satiation
signal to central food intake regulatory mechanisms (Read, French, & Cunningham,
1994). However, fat has a weaker effect than carbohydrate on satiety in humans and
experimental animals (Rolls et ah, 1994).
Carbohydrates are efficient appetite suppressants and contribute
markedly to the satiating efficiency of food (Rogers & Blundell, 1989). Carbohydratespecific appetites are attributed to low levels of the neurotransmitter serotonin in the
brain (Wurtman, et ah, 1985). NPY has recently been identified as a regulator of
carbohydrate intake in rats (Leibowitz, 1994). Additionally, the type of carbohydrate,
he., simple versus complex, influences the level of satiety in humans. Complex
27

carbohydrates that are slowly absorbed and cause a small but sustained increase in
blood glucose have greater satiation than rapidly absorbed carbohydrates (Raben, 1994).
3. Control Mechanisms of Food Intake
Diet-induced thermogenesis (DIT) and the release of pre- and postabsorptive signals are detected by the central nervous system and function in the
process of satiation. Strominger and Brobeck (1953) proposed the original thermostatic
hypothesis of feeding control which states that during food consumption heat released
through DIT increases body core temperature and results in termination of feeding,
however the role of DIT in regulating satiety remains to be established. The brain
regulates food intake through stimulation of the ventromedial and the lateral
hypothalamus, however several other anatomical sites in the brain participate in
regulating food intake through complex neural networks, neurotransmitters, and medial
hypothalamus-related neuropeptides, i.e., NPY, galanin, opioids and growth hormone
releasing factor (Anderson, 1994).
Mechanical, secretory, and receptive elements within the gastrointestinal
system contribute to the regulation of feeding behavior (Read et al., 1994).
Preabsorptive signals in the gut arise with food intake and may be transmitted to the
brain via the vagus nerve due to physical, chemical, osmotic, or hormonal responses
(Read et al., 1994). Low rates of gastric emptying occur with the consumption of high
total fat and high complex carbohydrate intakes, thus have the potential to influence
satiety. Release of food into the small intestine leads to the release of cholecystokinin
(Read et al., 1994), which slows gastric emptying and may interact with neural inputs to
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feeding centers in the brain. Lastly, digestion of macronutrients provides signals to the
brain via the vagus nerve through chemoreceptors in the wall of the small intestine.
Postabsorptive signals occur after food absorption due to the entry of
nutrients into the portal vein, or by fluctuations of nutrient concentrations in plasma or
the brain (Anderson, 1994). Peripheral glucose and amino acid levels have led to the
glucostatic and aminostatic theory of feeding, respectively. Mayer’s glucostatic theory
proposes that blood glucose reflects the availability of energy to the brain and other
tissues, thus controls food intake (1955). Human studies have shown an association
between declines in blood glucose and increased hunger (Campfield, 1992).
Insulin has been studied to determine it’s metabolic effects and direct
influence on the brain. Peripheral to the central nervous system, hyperinsulinemia is
associated with increased hunger, food intake and obesity (Heller, 1994), however
cerebral insulin action leads to the suppression of food intake (McGowan, Andrews, &
Grossman, 1992) in rats. Schwartz et al. (1993) found that insulin in the arcuate
nucleus is believed to inhibit the synthesis of hunger-related NPY due to reduced levels
of NPY mRNA, with subsequent reductions of NPY in the paraventricular nucleus.
Thus it is proposed that caloric deprivation reduces circulating and brain insulin, which
permits the increased production of NPY, and in turn stimulates feeding.
4. Measurement of Satiety
Silverstone (1982) validated the use of 100-mm visual analog scales
(VAS) for the subjective measurement of hunger and food intake. Numerous
researchers have since utilized VAS for the subjective measurement of appetite, hunger,
thirst, nausea, prospective consumption, and satiety (Blundell & Burley, 1987;
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Gielkens, Verkijk, Lam, Lamers, & Masclee, 1998; Rolls, Bell, Castellanos, Chow,
Pelkman, & Thorwart, 1999) before and after meals.
G. Future Research and Conclusions
Long-term controlled trials for weight reduction featuring hypocaloric HCLF
diets have been disappointing, i.e., the loss of body weight insufficient to compensate
for the HDL-lowering effect of the diet has occurred (Jones, Judd, Taylor, Campbell, &
Nair, 1987). Hence, an alternative dietary approach might include the use of MUFAenriched hypocaloric diets using either a high-oleic oil, or a nut, to potentiate a
favorable lipoprotein response during energy restriction. Zambon et al. (1999) found a
significant difference in lipoprotein subclass levels comparing an olive oil enriched
hypocaloric diet to a CHO-enriched hypocaloric diet. Since isocaloric almond feeding
trials have demonstrated hypocholesterolemic effects without changing HDL-C levels
significantly among hypercholesterolemic men and women (Spiller et al., 1990), the
incorporation of almonds into a medically supervised hypocaloric dietary regimen is
worth investigating. If the use of nuts produces favorable weight reduction and lipid
responses in the background of a hypocaloric diet, we will have an additional effective
strategy for treating the obese population worldwide.
There is no dispute that ample research exists showing that dietary fat can play a
role in the development of obesity. Since a reduction in dietary fat can significantly
reduce the difference between total energy intake and total energy expenditure, it is the
targeted macronutrient of choice to restrict in weight reduction programs. Willett
(1998) has noted that the dietary intake of fat and the prevalence of obesity has not been
positively correlated within geographic areas of similar economic development. The
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literature abounds with the results of short-term randomized trials that show that a
modest reduction in body weight occurs in individuals randomly assigned to diets with
a lower percentage of energy derived from fat. However, compensatory mechanisms
appear to operate as fat consumption within the range of 18-40% of energy appears to
have little if any effect on body fatness in clinical trials lasting greater than one year
(Willett, 1998).
Since the early 1970s, Americans’ average fat intake has decreased from over
40% of total calories to 34%, yet there has not been a concurrent improvement in health
(Taubes, 2001). The NIH started to encourage dietary fat restriction among the US
population in 1984, however Americans have failed to replace fat calories with fruits,
vegetables and legumes. Willett (1998) argues that the decline in the percentage of
energy from fat consumed during the past two decades in the US has corresponded with
a massive increase in the prevalence of obesity. Thus, high fat diets do not appear to be
the primary cause of the high prevalence of excess body fat among the US population,
and reductions in percent of energy from fat should not be promoted as the magic bullet
cure for obesity.
Almonds are 75% total fat by analysis, of which 72% is MUFA, mainly oleic
acid (C 18:1, n-9). Additional research is necessary to compare the effects of the
unique nutrient profile of almonds on plasma lipids and other cardiovascular risk factors
in obese adults under hypocaloric conditions. Future research should also explore the
effects of MUFA-enriched hypocaloric diets incorporating nuts versus conventional
HCLF diets on total body weight loss and compliance, through the measurement of
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satisfaction (i.e., satiety, taste and texture) during participation in comprehensive
medically supervised weight reduction programs.
In conclusion, clinicians treating obese adults become quickly frustrated with
the lack of novel dietary intervention strategies, as well as the high rate of recidivism, in
medically supervised weight reduction programs. The obese program participants that
are prescribed a partial or complete liquid protein supplement for protein-sparing effects
complain about insufficient food variety and lack of “crunch” at meal and/or snack
times. The incorporation of nuts into weight reducing diet plans has been avoided in the
past due to an inherent fear of the clinician in recommending the consumption of a
calorically dense food item within the construct of a low calorie diet. Thus, to discount
the fallacy that nuts are fattening, and to appease the desire of the obese client for more
options with crunchy texture, in dietary interventions incorporating nuts must be tested
and validated in the free-living population.
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CHAPTER 3
METHODS
A.

Subjects and Design
The study sample was a sample of convenience, as research participants must

have been concurrently enrolled in the 24-week D & CVRRP at COH. Prospective
research participants were identified during the D & CVRRP screening process with the
cooperation of the D & CVRRP Program Coordinator and Program endocrinologists.
Once the Program Coordinator or Program endocrinologist referred the patient to the
Principal Investigator (PI), the PI approached the patient, verified their willingness to
participate in the research study, and obtained written informed consent.
Potential research participants had the opportunity to take the COH Institutional
Review Board (IRB) approved Informed Consent form home with them before deciding
to participate in the study to enable them to discuss participation in the study with their
family, friends or other confidants prior to signing the study consent form. The PI
followed up within 24 hours of explaining the Informed Consent form to the potential
research participants.
All research participants followed standard informed consent procedures as
identified by the COH Research Subjects Protection Office. Notification of the intent to
do research at COH using a COH IRB approved Informed Consent was provided in
writing to the Loma Linda University IRB according to the Multiple Project Assurance
M-1295 guidelines.
Research participants were given a copy of the Experimental Subjects' Bill of
Rights to read and sign in accordance with California State Law. Research participants
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were given a written copy of the study Informed Consent to read and sign and were
given a signed copy to keep. A witness signed and dated the study Informed Consent
form to attest that the requirements for informed consent were satisfied. A copy was
given to the person who attested to the form. Once signed consent had been obtained,
research participants were randomized and entered into the study.
Research participant recruitment was open to all minorities and both genders.
Based on the previous seven years of D & CVRRP operation, the sample size was
anticipated to include 70% women. Females of childbearing potential and/or pregnant
women were excluded from the study as the effects of very low calorie (protein sparing
modified fast) diets on the fetus are unknown. In 1998, the COH total population
included 39% ethnic minorities of which 20% were Hispanic (predominant minority
group).
A statistical analysis of the data of patients previously enrolled in the D &
CVRRP during 1998 and 1999 (males, pre-menopausal women and post-menopausal
women not receiving hormone replacement therapy) revealed a baseline mean HDL-C
of 43.9 mg/dl with a standard deviation of 12.2 mg/dl. No significant difference in
HDL-C at baseline was found across gender or menopausal status in these patients.
The research study featured a randomized two group pretest-posttest
experimental design. The notation for this research design is shown below (Cook and
Campbell, 1979).
R Oi X! 02
R Oi X2 02
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Randomization of subjects is denoted by R, observation at baseline and 24
weeks is denoted by Oi and O2 respectively, and, the dietary interventions HCLF and
LCHF are denoted by Xi and X2 respectively.
Research participants were randomized into the almond or complex
carbohydrate (CHO) group according to the registration procedures in Appendix A.
The COH Department of Biostatistics utilized a Fortran software program developed at
Stanford University entitled Random Number Generation (RNDGEN). The
randomization schema featured stratification according to gender and presence or
absence of diabetes across the two study groups.
The two study groups had different levels of monounsaturated fat due to the
distinct dietary components prescribed. However, both groups were equally balanced
on total calories and featured the use of the same amount of prescribed liquid protein
supplement. Table 1 below shows the prescribed supplement, vitamins and foods for the
complex carbohydrate and almond group.
Table 1. Prescribed Supplement, Vitamins and Foods for the Complex Carbohydrate
and Almond Group
Almond group
Complex carbohydrate group
4 packages of Health Management
4 packages of Health Management
Resources (HMR) 70 Plus
Resources (HMR) 70 Plus
2 HMR vitamin/mineral supplements
2 HMR vitamin/mineral supplements
Salad with 2 cups lettuce, 1 cup fresh
Salad with 2 cups lettuce, 1 cup fresh
tomato, 1 cup fresh celery, vinegar/lemon tomato, 1 cup fresh celery,
vinegar/lemon juice
juice
3 ounces (84 grams) almonds
2 teaspoons standard safflower oil
Complex carbohydrates (see Appendix B)

Health Management Resources (HMR) 70 Plus is a commercially available
protein sparing formulation prescribed during energy restriction to ameliorate the loss
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of lean body mass (LBM). HMR 70 Plus contains minimal simple CHO (sucrose and
fructose) for palatability, however is not a significant dietary source of complex CHO.
The amount of HMR 70 Plus prescribed was individually tailored to the requirements of
the participant to achieve a daily intake of 1.0 to 1.4 grams of protein per kilogram ideal
body weight (IBW). All research participants were required to consume their
prescribed HMR 70 Plus formula daily to spare LBM loss.
The nutrient analysis for the information in the tables below were performed
using Food Processor for Windows (Version 7.11). Table 2 compares the nutritional
profile of four packages of the HMR 70 Plus product and 2 HMR vitamin/mineral
supplements versus one package of HMR 70 Plus.
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Table 2. Nutritional Analysis of HMR 70 Plus and Vitamin/Mineral Supplementation
1 package HMR 70 Plus
Nutrient
4 packages HMR 70 Plus
+ 2 HMR vitamin/mineral
supplements
104
416
Energy, kcal
14
56
Protein, g
50
12.6
Carbohydrate, g
0.2
0.8
Total fat, g
Negligible
Negligible
Saturated fat, g
2.8
0.7
Fiber, g
4
1
Cholesterol, mg
764
156
Sodium, mg
172
688
Potassium, mg
4
0
Manganese, mg
300
1200
Calcium, mg
200
800
Phosphorus, mg
444
36
Magnesium, mg
0
22.5
Zinc, mg
0
3
Copper, mg
0
5000
Vitamin A, I.U.
60
340
Vitamin D, I.U.
0
45
Vitamin E, I.U.
0
84
Vitamin C, mg
0
400
Folic acid, meg
0
1.8
Thiamin, mg
0.34
1.7
Riboflavin, mg
0
30
Niacin, mg
0
3
Vitamin B6, mg
0
9
Vitamin B12, meg
0
15
Pantothenic acid, mg
0
450
Biotin, meg
0
150
Iodine, meg
0
27
Iron, mg
0
100
Vitamin K, meg
0
150
Selenium, meg
0
150
Chromium, meg
0
300
Molybdenum, meg

Table 3 compares 2 teaspoons safflower oil + 1 !4 cup peas +15 Triscuits™
versus 84 grams of almonds. These are the uncommon dietary elements of the two
treatments, thus this represents the difference in nutrients in the two groups. The
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imbalance in vitamin A, vitamin E and folic acid was noted and a rationale for
supplementation was investigated. In light of no known interactions of these
macronutrients on the metabolic and anthropometric parameters under investigation in
this study, vitamin supplementation was not pursued.

Table 3. Nutrient Composition of the Almond Supplement and the Complex
Carbohydrate Dietary Counterpart of the Study Diets
Complex carbohydrate group
Almond group
Nutrient
(2 teaspoons safflower oil +
(84 grams almonds)
1 V2 cup peas + 15 wheat crackers)
508
495
Energy, kcal
17
17
Protein, g
75
17
Carbohydrate, g
44
18
Total Fat, g
4
2
Saturated fat, g
9
20
Fiber, g
0
0
Cholesterol, mg
532
9
Sodium, mg
615
485
Potassium, mg
2
2
Manganese, mg
223
72
Calcium, mg
437
337
Phosphorus, mg
249
112
Magnesium, mg
2.4
3
Zinc, mg
1
0.5
Copper, mg
0
1603
Vitamin A, I.U.
0
0
Vitamin D, I.U.
30
9.7
Vitamin E, I.U.
1
24
Vitamin C, mg
49
157
Folic acid, meg
0.2
1
Thiamin, mg
0.65
0.42
Riboflavin, mg
2.8
6.3
Niacin, mg
0.1
0.4
Vitamin B6, mg
0
0.6
Vitamin B12, meg
0.4
0.9
Pantothenic acid, mg
54
1
Biotin, meg
1.7
4.8
Iodine, meg
3
5.8
Iron, mg
4
11
Selenium, meg
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A comparison of the nutrient profile of the two prescribed dietary interventions
is shown in Table 4 below.
Table 4. Nutrient Composition of the Study Diets
Complex carbohydrate
Nutrient
group
Energy, kcal
1015 kcal
18%
% kcal from fat
53%
% kcal from carbohydrate
22 grams
Fat
144 grams
Carbohydrate
Protein
78 grams
32 grams
Fiber
3 grams (3%)
Saturated fat
6 grams (5%)
Monounsaturated fat
Polyunsaturated fat
9 grams (11%)
4 mg
Cholesterol
556 mg
Magnesium
1.16
grams
Arginine
4.76 grams
Lysine
4.1
Lysine/arginine ratio
8.4 mg
Vitamin E-alpha equivalent

Almond group
1012 kcal
39%
32%

46 grams
85 grams
78 grams
20 grams
3 grams (3%)
28 grams (25%)
10 grams (9%)
4 mg
693 mg
2.23 grams
4.47 grams
2

18.7 mg

Research participants were instructed to discontinue their intake of all non
prescription vitamin/mineral supplements one month prior to study initiation to allow a
wash out period. Research participants were also instructed to take two HMR
vitamin/mineral supplement tablets two weeks prior to study initiation to allow a twoweek run-in period.
During week one of the 24-week program/study, research participants were
given explicit guidelines on their prescribed daily FIMR formula, HMR vitamin/mineral
supplements, food and fluid intake. Appendix C provides a description of the General
Dietary Guidelines provided to the research participants.
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Nutrition education, behavior modification and exercise classes were provided
weekly on a rotating basis to facilitate weight loss and maintenance. Nutrition
education and behavior modification classes were taught by the Program Dietitian (PI)
and Program Psychologist, respectively, to enable the patient to integrate new behaviors
that facilitate weight reduction and maintenance into his/her current lifestyle. Exercise
classes were taught by a Registered Physical Therapist to enable the research
participants to develop a personalized exercise program.
To assure the safety of their health, research participants signed a D & CVRRP
contract (Appendix D) ensuring the consumption of all the formula/food prescribed, and
agreed to attend scheduled appointments for the duration of the program. Two
consecutive scheduled weekly absences or five non-consecutive visits or portions of
visits during the 24-week program cycle were grounds for discharge from the program
and study.
Compliance to the dietary regimen and body weight were carefully monitored.
Research participants had a time commitment in the outpatient clinic every Wednesday
from 3:45 p.m. to 6:00 p.m. for a brief physician visit that was required after
measurements of blood pressure, weight, blood ketones and blood glucose were taken.
The Program Dietitian, Program Psychologist and Physical Therapist were available for
short consultations upon research participant or physician request. Failure to achieve a
one to two pound per week average weight loss, inability to maintain a mild ketotic
state, or, a high blood glucose (in type 2 diabetes research participants) were potential
signs of dietary and exercise non-compliance. These situations warranted the

40

scheduling of an intermediate-length consultation with the Program Dietitian and/or the
Program Psychologist.
In addition to the blood ketone and blood glucose measures of dietary
compliance, research participants completed daily food and exercise records for weekly
review by the Program Dietitian. Daily reporting of the following was recorded by
research participants using the D & CVRRP calorie and exercise record book: HMR
formula intake, fluid intake, intake of prescribed and/or non-prescribed foods, time of
day meals or snacks were consumed, computation of daily total caloric intake according
to the Program Dietitian’s guidelines, and, type and duration of exercise (minutes).
Additionally, research participants were asked to subjectively evaluate and record the
acceptability of their dietary regimen in terms of satiety, palatability and texture using a
questionnaire at baseline, week 8, 16 and 24 (Appendix E). Validation of the
instrument is discussed in Section H. 1.
Research participants who failed to bring their weekly record book to clinic
were advised to mail the book to the Program Coordinator within 24 hours. Research
participants who failed to perform the daily food and exercise recording received a
warning from the physician and were scheduled for private counseling sessions with the
Program Psychologist to improve record-keeping compliance.
B.

Research Variables
Almonds and complex CHO were the sources of the macronutrients manipulated

in this study, hence are the independent variables. The outcome (dependent) variables
were TC, HDL, TG, HDL-C, HDL-TG, LDL-C, LDL-TG, VLDL-C, VLDL-TG,
glucose, insulin, HgbAlc, blood ketones, total body weight loss, waist-to-hip ratio
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(WHR), waist circumference, percent body fat, fat mass (FM), fat free mass (FFM),
total body water (TBW) and blood pressure.
C.

Anthropometric and Body Composition Methodology
To determine if an individual is obese versus simply overweight due to

increased muscle mass, multiple techniques and standards for quantitating body weight,
body fat, and distribution of body fat should be utilized. Anthropometric measurements
were performed including height and weight and circumferences of the waist and hip.
Height and weight measurements provide an estimate of the degree of obesity, whereas
the WHR and waist circumference provide practical measures for estimation of regional
fat distribution. Bioelectrical impedance analysis (BIA) using the Tanita® TBF-300
body composition analyzer scale was performed to derive measurements of body
composition.
1. Weight and Height Measurements
Fat-free mass or lean body mass (LBM) comprises 70-90% of body
weight, hence LBM and weight should be related (Forbes, 1996). Likewise, in an obese
population with widely variable fat content, body fat and weight should also be related.
The outpatient clinic assistant measured body weight twice to the nearest 0.05 kg at
each weekly clinic visit using the COH Outpatient Clinic Digital Scaletronic™ scale.
The average of the two measurements was recorded in the medical record. Clinic scales
were calibrated weekly by the COH Biomedical Instrumentation Systems division.
Weights were taken with the patient wearing minimal street clothing and no shoes.
Height was measured on the first clinic visit using the outpatient clinic wall mounted
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stadiometer. Patients were measured twice without shoes and the average of the two
measurements was recorded.
2. Girth Measurements
Waist circumference is an index of regional fat distribution and is related
to fat-free mass. When used in a ratio with the buttock (hip) circumference, waist
circumference is an indicator of the degree of the android distribution of adipose tissue.
Above normal ratios are considered to constitute an increased risk of heart disease and
type 2 diabetes. The buttocks (hip) circumference is a measurement of the external
pelvic size that reflects the amount of adipose tissue in the region. Adipose tissue in
this region is largely subcutaneous and relates to the lower segment of the body.
Waist and buttocks (hip) circumference measurements were taken according to
guidelines in the Anthropometric Standardization Reference Manual (Lohman, Roche,
& Martorell, 1991). Two measurements of the waist and buttocks (hip) were taken at
baseline and at 24 weeks.
Research participants were advised to wear loose-fitting clothing so that the tape
measure could be correctly positioned and were advised to stand erect with abdomen
relaxed, arms at the sides and feet together. The PI faced the research participant and
placed the inelastic tape around them, in a horizontal plane, at the level of the natural
waist (narrowest part of the torso) as seen from the anterior aspect. The measurement
was taken at the end of a normal expiration, without the tape compressing the skin, and
recorded to the nearest 0.1 cm. In some research participants it was difficult to identify
a waist narrowing. In such cases, the smallest horizontal circumference was measured
in the area between the ribs and iliac crest. To determine the hip circumference the PI
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squatted at the side of the patient so that the level of maximum extension of the buttocks
could be seen. An inelastic tape was placed around the buttocks in a horizontal plane at
this level without the tape compressing the skin and the measurement was recorded to
the nearest 0.1 cm.
3. Bioelectrical Impedance Analysis
Bioelectrical impedance analysis (BIA) was performed by the PI on the
research participants at baseline and 24-weeks during pre-scheduled appointments in the
COH GCRC clinic. BIA was performed using the Tanita® TBF-300 body composition
analyzer/scale which utilizes "foot-to-foot" pressure contact electrode technology to
determine internal body composition (Nunez, 1997). BIA technology is based upon the
principle that lean tissues contain a high electrolyte and water content which provides a
good electrical pathway as compared to fat mass which contains a lower percentage of
body water (Heyward, 1996). First, a measurement of the baseline resistance to the
electrical current flow is made by inducing a low energy, high frequency, electrical
signal (50 kHz, 500 microamp). The current is then passed through the anterior
electrode on the platform of the Tanita® scale and the drop in voltage is measured on
the scale’s posterior electrode. The volume of the conductor correlates with the
resistance measurement which is used to determine TBW, FFM, and FM. A proprietary
formula derives the percent body fat by combining impedance and weight
measurements with height, gender, age and physical activity level.
The manufacturers’ instructions were followed for the estimation of
percent body fat at baseline and week 24. Research participants were instructed to
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avoid alcohol 48 hours before the test, fast for 12 hours, avoid intense exercise 12 hours
before the test, and to empty their bladder 30 minutes before the test.
D.

Lipoprotein Quantification (LPQ) and Lipid Panel
Fasting blood was collected at weeks 0, 8, 16 and 24. Plasma variables were

determined from venous blood drawn after a 12-hour fast. Venous blood was collected
in appropriately treated tubes and plasma was obtained by use of a Beckman Allegra™
21 centrifuge at 2500 revolutions per minute for 15 minutes at 4° C by the GCRC
technician at COH. The Lipids Laboratory within the School of Pharmacy, Department
of Molecular Pharmacology and Toxicology at the University of Southern California
performed the Lipid Panel and Lipoprotein Quantification analysis using a TL100
Beckman Ultracentrafuge and a Cobas MIRAS analyzer (Roche). See Appendix F for
collaborating laboratory procedures for the separation of LPQ, total cholesterol and
triglycerides analysis using the Cobas machine, and HDL analysis by the precipitation
method.
E.

Blood Ketone and Blood Pressure Testing
Using fmgerstick methodology, COH outpatient clinic nurses took blood ketone

measurements during weekly clinic visits using a calibrated Hemocue™ monitor. Blood
pressure measurements were taken by outpatient clinic nurses using automated blood
pressure devices in the clinic.
F.

Additional Testing
The GCRC technician produced the aliquots for additional tests and aliquots

were stored at -70°. Plasma insulin levels were determined by human specific
radioimmunoassay (Linco kits) methodology at COH, and plasma glucose levels were
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determined by a Stat Glucose/Lactate Analyzer Model 2000 (YSI, Yellow Springs,
Ohio).
G.

Instrumentation
1.

Development of Satiety and Satisfaction Questionnaire
A questionnaire was developed to measure the research participant’s

level of satiety and satisfaction to the “diet” prior to the start of the D & CVRRP
(baseline) and at weeks 8, 16 and 24. In addition to three questions which addressed
self-reported feelings of hunger and fullness one to two hours after breakfast, lunch and
dinner, research participants were also asked to rate how satisfied they were with the
taste and texture of their prescribed diet.
Three months prior to study enrollment, the preliminary questionnaire
was discussed with Dr. Marsha Grant of the COH Department of Nursing Research.
Dr. Grant has an extensive background in instrument validation. The preliminary tool
was found to address the construct of satiety and to assess dietary taste and texture.
Twenty-two D & CVRRP patients were asked to fill out the preliminary questionnaire
for two consecutive days to provide for a test-retest analysis. Thus, the tool was
validated among the same population for which it was designed. Using the criteria that
if the difference is less than 1.0, there is agreement in the “raw agreement score” on day
1 and day 2, the average of the agreements within patients on day 1 and day 2 were
found to be as follows: question 1, r = 0.692; question 2, r = 0.692; question 3, r =
0.769; question 4, r = 0.846; and, question 5, r = 0.846. Thus, all five questions were
retained for the instrument.
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H.

Data Collection
Data was collected for database entry using data collection forms (Appendix G)

for demographic information, lipid analysis data, non-lipid analysis data,
BIA/anthropometric data and questionnaire data. Source documents included the
research participants medical record, lipid analysis spread sheets from the USC Lipids
Laboratory, data provided from the COH lab technicians, and printed output from the
Tanita® body composition analyzer/scale and questionnaires.
I.

Data Analysis
The primary study hypothesis was as follows: There will be a significant

difference in HDL-C, hence the LDL-C/HDL-C ratio in obese adults consuming a
MUFA-enriched hypocaloric diet using almonds versus a complex CHO-enriched
hypocaloric diet during a medically supervised 24-week weight reduction program.
Sample size and power calculations were performed utilizing UnifyPower
Macro for SAS. To detect a 10% effect size in HDL-C with power = 80%, and a = .05
(two-sided), 42 participants were required in each group for a total of 84 participants.
Allowing for a 10% dropout rate (historical), we needed approximately 92 participants,
46 per group. Considering the specified exclusion criteria (see Appendix H), dropout
rate, and, the present rate of D & CYRRP patient accrual, total target accrual should
have been achieved within 12 months of COH Institutional Review Board approval.
The analysis that was planned to be used to test the primary hypothesis was an
independent 2-sample t-test to compare differences between lipids at baseline and at 24
weeks across groups, as well as a paired t-test (post- vs. pre-) to compare differences
across time between lipids at 24-weeks and baseline. Multiple baseline measurements
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were to be pooled to deflate the effect of intra-personal variation on the blood profiles.
ANOVA was to be used for the analysis of the multiple comparisons at baseline, 8, 16
and 24 weeks (repeated measures). If the assumption of equal variances was not met,
the Mann-Whitney rank sum test would be used. Time to response curves were to be
evaluated as a component of the descriptive statistics. The primary analysis was to be
based on intent-to-treat, however a secondary “as treated” analysis would also be
performed.
Data was entered into a IMP database (Version 4.0.5) and statistical analysis
was performed using SAS (Version 8.2).

Due to the longitudinal structure of the

data, a repeated measures mixed model with an autoregressive covariance structure of
lag 1 was chosen to test all hypotheses, including those involving multiple covariates.
This type of model would model the covariance structure within subjects, incorporating
submatrices corresponding to each subject in each group. This would allow the within
subject error to be accounted for and to be separated from the overall error, allowing for
a more accurate and sensitive test of each hypothesis. Autoregrssive (order 1)
covariance structure specifies that the covariance between two measurements w time
intervals apart is a p. The parameter ct represents the variance of an observation, Var
(Yijk) = cr . The parameter p represents the correlation between adjacent observations
on the same subject. Thus, the correlation between measurements at times one and two
is p, between measurements at times one and three is p2, and between measurements at
times one and four is p3.
All models were adjusted for baseline measurements of the variable of interest,
and all four time points (0, 8, 16 and 24 weeks) were included in the analysis.
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Descriptive statistics were used to summarize the patient population. A table
summarizing the effect of all major endpoints was created, with the least squares means,
standard error, percent change and absolute change given for time points 0 and 24
weeks, with p-values given for the overall model, which included all time points. All pvalues are based on Type III tests of fixed effects, which ensures that the addition of the
variable of interest was added into the models after controlling for all other variables.
Visual display of the effect of each treatment on each endpoint over time was achieved
through plotting the least squares mean and 95% confidence interval (Cl) by treatment
group over time for each endpoint.
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CHAPTER 4
RESULTS
A. Enrollment
Patients (n=57) were randomized into the 2 intervention groups according to
gender and presence or absence of diabetes mellitus (Figure 1). The tight eligibility
criteria produced 68% of the total targeted accrual over a 24-month period. The
patients completing the 24-week study (n=46) were evenly distributed across the two
groups. The proportions of withdrawals from the almond and complex carbohydrate
(CHO) group were similar, 6 from the almond group and 5 from the CHO group.
Primary reasons for dropping out of the study included work conflicts and worsening
plasma lipid levels necessitating the resumption of pre-study anti-hyperlipemic agents.
36 patients were Caucasian, 10 Hispanic, 6 African American, and 5 Asian.
Demographic, anthropometric, and baseline characteristics were similar in the two
intervention groups after randomization (Table 5). The pre-program clinical
characteristics of the research participants were not statistically significant at baseline
with the exception of a higher number of hypertensive patients having been assigned to
the CHO group compared to the almond group.
B. Anthropometric Measurements and Insulin Sensitivity
Using an intent-to-treat analysis, Table 6 shows the means and standard error of
the means (SEM) for the anthropometric parameters in research participants enrolled in
the study at baseline and week 24. During the 24-week treatment period, mean weight
loss was 15.73 kg (14%) for the almond group (95% Cl, -30.73 to -0.73 kg) and 11.64
kg (11%) for the CHO group (95% Cl, -27.36 to 0 kg). The mean plasma insulin.
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plasma glucose, insulimglucose ratio (IGR) and HgbAlc values are shown in Table 7.
Table 8 shows the mixed model results for the anthropometric and metabolic parameters
for both groups. There was a statistically significant difference in weight loss in the
almond group as compared with the CHO group over time, -18.02% in the almond
group vs.
-10.35% in the CHO group (P < 0.0001). Improvement in anthropometric parameters
occurred due to the changes in body weight and contributed to greater improvements in
the cardiovascular disease risk profile in the almond group as compared to the CHO
group over time. Research participants in the almond group also achieved a statistically
significant difference in reduction in BMI, waist circumference and fat mass, -17.53%
in the almond group vs. -10.67% in the CHO group (p < 0.0001), -14.06% in the
almond group vs. -9.29% in the CHO group (p = 0.0255) and -30.32% in the almond
group vs. -19.53% in the CHO group (p = 0.0205) respectively.
Both groups experienced a reduction in the waisthip ratio, percent fat, fat free
mass and total body water over time, -3.26% and -3.26% (p = 0.0003), -15.76% and
-11.09% (pO.OOOl), -8.21% and -3.85% (pO.OOOl), and, -8.10% and-1.33% (p =
0.0034) for the almond and CHO group respectively. However, no statistically
significant difference in any of these parameters was found between the two groups.
Table 9 shows the results of evaluating the outcome variable weight among the
two groups after single adjustment for either gender, diabetes or hypertension in
contrast to the group by time effect. Gender of the research participant or influence of
chronic disease (diabetes mellitus, hypertension) were not independently responsible for
the weight difference found between the two groups.
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Both groups demonstrated a reduction in insulin, glucose, insulimglucose ratio
(IGR) and HgbAlc over time, -57.83% and -34.61% (pO.OOOl), -18.80% and -14.07%
(p = 0.0006), -47.06% and -27.03% (p = 0.0008) and -14.85% and -12.41% (pO.OOOl)
for the almond and CHO group, respectively. However, no statistically significant
difference in any of these parameters was found between the two groups.
C. Cardiovascular Risk Factors
Tables 10 and 11 show the mean plasma lipid levels in the almond and CHO
groups at weeks 0, 8, 16 and 24, respectively. Plasma lipids at baseline (week 0) were
not statistically significantly different between the two groups. The mean TC:HDL ratio
declined from 4.65 to 3.90 in the almond group and 4.77 to 4.21 in the CHO group
during the 24-week study period.
Summary statistics for the plasma lipids are shown in Table 12. No statistically
significant difference between the groups was found for any lipid parameter that was
measured. However, both groups demonstrated a statistically significant reduction over
time in TC (p < 0.0001), TG (p = 0.0024), VLDL-C (p = 0.0386), LDL-C (p< 0.0001),
VLDL-TG (p = 0.0028), TC:HDL (p = 0.0022) and LDL-C:HDL-C (p = 0.0268).
There was no significant difference over time in HDL (p = 0.7848), HDL-TG (p =
0.5140) or HDL-C (p = 0.2004).
Table 13 shows the mean blood pressure levels observed at week 0 and 24 in the
two groups. Mixed model results (Table 14) reflected a statistically significant
reduction in both groups over time for systolic (p = 0.0506) and diastolic (p = 0.0371)
blood pressure. However, no statistically significant difference in blood pressure was
found between the two groups.
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D. Other Factors
Table 8 shows the summary statistics for blood ketone levels in the two groups.
Ketone levels were statistically significantly increased in the almond group (+250%) as
compared to no change within the CHO group (p = 0.0230).
The research participants did not differ in their self-reported evaluation of the
acceptability of their dietary regimen in terms of satiety, palatability and texture using a
10-point scale at baseline and weeks 0, 8, 16 and 24. The responses to the questionnaire
(Appendix E) were evaluated according to meal, i.e. breakfast, lunch, dinner, across the
two study groups over the 24-week study period. Table 15 shows a summary of the
questionnaire scoring results for the three questions evaluating satiety. Non-significant
results were found across the two study groups over time. In comparison to the research
participant’s baseline diet, this finding reflects the ability of either almonds or complex
carbohydrates to maintain satiety 1 to 2 hours after meals over at least 24 weeks.
Additionally, taste and texture of the two distinct interventions did not significantly
change from baseline over the 24-week study. Table 16 shows a summary of the
questionnaire scoring results for the two questions evaluating texture and taste
satisfaction.
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58 Patients
Eligible for
D&CVRRP
1 Did Not Meet
Lipid Criteria
57 Patients Were
Randomly Assigned

Almond Diet
(28 Patients)

Complex CHO Diet
(29 Patients)

6 Withdrew
5 Work Conflict
1 Returned to Anti-lipemic
Medication

5 Withdrew
4 Work Conflict
1 Returned to Anti-lipemic
Medication

22 Completed Trial

24 Completed Trial

28 Included in Intention-toTreat Analysis
22 Included in per Protocol
Analysis

29 Included in Intention-toTreat Analysis
24 Included in per Protocol
Analysis

Figure 1. Flow of Patients Throughout the Trial
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Table 5. Pre-Program Clinical Characteristics of the Research Participants3
Almond group
CHO group
28(16/12)
29(18/11)
n(F/M)
21/8
20/8
Type 2 diabetes (Y/N)
19/10
11/17
Hypertension (Y/N)
55 ±2
53 ±2
Age (years)
Anthropometries
Weight (kg)
Weight (lbs)
BMI(kg/m2)
Waist-to-hip ratio
Waist circumference (in)
% body fat
Fat mass (lbs)
Fat free mass (lbs)
Total body water (lbs)

113.48 ±5.24
249.65 ± 11.53
38.45 ± 1.48
0.93 ± 0.02
48.33 ± 1.56
41.59± 1.39
104.67 ±6.83
144.97 ±7.00
106.13 ±5.12

103.6 ±5.21
227.92 ± 11.47
35.92 ± 1.34
0.91 ±0.01
45.85 ± 1.52
42.56 ± 1.30
97.97 ± 6.63
129.17 ±6.65
92.39 ±5.73

Insulin (pU/ml)
Glucose (mg/dl)
Insulin: Glucose
HgbAlC
Ketones
BPs (mmHg)
BPd (mmHg)

50.41 ± 9.05
161.4± 13.59
0.34 ±0.05
8.60 ± 0.30
0.10 ±0.02
144.14 ±3.24
77.93 ± 2.20

49.89 ±6.59
153.17± 13.70
0.37 ±0.05
8.58 ± 0.37
0.10± 0.01
135.55 ±3.72
77.11 ±2.66

Plasma lipids5
194.55 ±7.67
215.75 ±8.16
Total cholesterol (mg/dl)
44.41 ± 1.92
46.28 ±2.01
HDL (mg/dl)
203.25 ±20.86
178.33 ± 19.11
Triglycerides (mg/dl)
4.77 ±0.25
4.65 ± 0.23
Total cholesterol:HDL
40.52 ±3.23
48.00 ±4.59
VLDL-C (mg/dl)
105.43 ±5.53
97.85 ±5.01
LDL-C (mg/dl)
32.87 ± 1.69
31.93 ± 1.68
HDL-C (mg/dl)
3.41 ±0.23
3.17 ± 0.16
LDL-C:HDL-C
118.41 ± 15.57
135.83 ± 15.37
VLDL-TG (mg/dl)
33.47 ± 1.70
29.81 ±2.02
LDL-TG (mg/dl)
11.11 ±0.33
12.13 ±0.43
HDL-TG (mg/dl)
Characteristics were taken at week 0.
bTo convert from mg/dl to mmol/1, divide cholesterol values by 38.67 and triglyceride
values by 88.54.
Note: Data are means ± SE unless otherwise indicated
SE = standard error
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Table 6. Change in Anthropometric Parameters in the Research Participants
Almond group
Week 0 (n = 28)
Week 24 (n = 22)

CHO group
Week 0 (n = 29)
Week 24 (n - 24)

Weight (kg)
Weight (lbs)
BMI (kg/m2)
Waist:Hip ratio
Waist circumference (in)
% Body fat
Fat mass (lbs)
Fat free mass (lbs)
Total body water (lbs)

103.6 ±5.21
227.92 ± 11.47
35.92 ± 1.34
0.91 ±0.01
45.85 ± 1.52
42.56 ± 1.30
97.97 ±6.63
129.17 ±6.65
92.39 ±5.73

113.48 ±5.24
249.65 ± 11.53
38.45 ± 1.48
0.93 ± 0.02
48.33 ± 1.56
41.59± 1.39
104.67 ±6.83
144.97 ± 7.00
106.13 ±5.12

97.75 ± 5.26ft
215.05 ± 11.58ff
32.84 ± 1.45ft
0.90 ± O.Olf
42.59 ± 1.34ft
34.96 ± 2.04f
76.86 ± 7.66ft
138.19 ±7.23f
101.15 ±5.30f

fp< 0.05, for the contrasts from week 0 to 24 for the changes over time within groups
tp< 0.05, for the contrasts from week 0 to 24 for the changes over time between groups
Note: Data are means ± SEM
SEM = standard error of the mean

91.96 ± 5.72ft
202.31 ± 12.58ft
32.63 ± 1.49ft
0.88 ± 0.02f
41.40 ± 1.73ft
38.63 ± 1.59f
79.94 ± 6.86f
122.36 ±7.24f
89.57 ±5.30

Table 7. Change in Plasma Insulin, Glucose, Insulin:Glucose Ratio, Blood Ketones and HgbAlc in the Research Participants
Almond group
Week 0 (n - 28)
Week 8 (n = 26)
Week 16 (n = 23)
Week 24 (n = 22)
Insulin (pU/ml)
Glucose (mg/dl)
Insulin:Glucose ratio
Ketones (mmol/L)
HgbAlc (n = 20)
Carbohydrate group

'-4

50.41 ±9.05
161.4 ± 13.59
0.34 ±0.05
0.01 ±0.04
8.61 ±0.30

26.37 ±2.52
133.76 ±9.57
0.21 ±0.02
0.28 ± 0.04
Not performed

21.89± 1.87
119.96 ±7.95
0.19 ±0.01
0.33 ±0.05
Not performed

21.54 ± 1.87f
123.45 ±7.99f
0.18 ± 0.021
0.38 ± 0.05tt
7.35 ± 0.43t

Week 0 (n = 29)

Week 8 (n = 27)

Week 16 (n = 24)

Week 24 (n = 24)

Insulin (pU/ml)
35.29 ±4.41
27.81 ±3.10
49.89 ±6.59
Glucose (mg/dl)
138.21 ± 11.68
138.54 ± 13.72
153.17 ± 13.70
Insulin:Glucose ratio
0.37 ±0.05
0.30 ±0.37
0.23 ± 0.03
Ketones (mmol/L)
0.10 ±0.04
0.11 ±0.04
0.14 ±0.05
HgbAlc (n = 21)
8.58 ±0.37
Not performed
Not performed
fp< 0.05, for the contrasts from week 0 to 24 for the changes over time within groups
Jp< 0.05, for the contrasts from week 0 to 24 for the changes over time between groups
Note: Data are means ± SEM
SEM = standard error of mean

32.33 ± 5.46
130.67 ± 12.02t
0.27 ± 0.05
0.11 ±0.05J
7.62 ± 0.37f

00

Table 8. Summary Statistics for Anthropometric and Metabolic Parameters
Variable
Week
Almond
Carbohydrate
% change =
LSM (SE)
week 24 - week 0
(CHO)
(n = 28)
LSM (SE)
week 0
(n = 29)
Almond CHO
Weight
0
246.16(1.92) 245.79(1.92) -18.02
-10.35
(lbs.)
24
201.79 (2.35) 220.36(2.31)
BMI
0
37.60 (0.41)
37.38 (0.42)
-10.67
-17.53
(kg/m2)
24
31.01 (0.47)
33.39 (0.46)
Waist (in.)
0
47.43 (0.46)
47.13 (0.47)
-9.29
-14.06
24
40.76 (0.53)
42.75 (0.52)
Waist: hip
0
0.92 (0.01)
0.92 (0.01)
-3.26
-3.26
24
0.89 (0.01)
0.89 (0.01)
% fat
0
42.20 (0.60)
42.20 (0.60)
-15.76
-11.09
24
35.55 (0.68)
37.52 (0.60)
Fat mass
0
102.61 (2.20) 102.30(2.20) -30.32
-19.53
(lbs.)
24
71.50 (2.48)
82.10(2.42)
Fat free
0
138.11 (1.39) 137.31 (1.40) -8.21
-3.85
mass (lbs.)
24
126.77 (1.58) 132.02 (1.54)
0
Total body
100.30 (1.45) 98.88 (1.45)
-8.10
-1.33
water (lbs.)
24
92.18 (1.64)
97.56(1.60)
Insulin
0
50.42 (5.07)
49.79 (4.98)
-57.83
-34.61
24
21.26 (5.52)
(pU/ml)
32.56 (5.29)
Glucose
0
161.30(11.43) 152.12(11.66) -18.80
-14.07
(mg/dl)
24
130.97(11.78) 130.72(11.68)
Insulin:
0
0.34 (0.04)
0.37 (0.04)
-47.06
-27.03
Glucose
24
0.18(0.04)
0.27 (0.04)

Absolute change =
week 24 - week 0

P valuej
time
effect

-44.37

CHO
-25.43

P valuef
group
x time
effect
<0.0001*

-6.59

-3.99

<0.0001*

<0.0001*

-6.67

-4.38

0.0255*

<0.0001*

-0.03

-0.03

0.5656

0.0003*

-6.65

-4.68

0.1263

<0.0001*

-31.11

-19.93

0.0205*

<0.0001*

-11.34

-5.29

0.0453*

<0.0001*

-8.12

-1.32

0.0312*

0.0034*

-29.16

-17.23

0.5966

<0.0001*

-30.33

-21.40

0.4093

0.0006*

-0.16

-0.10

0.6866

0.0008*

Almond

<0.0001*

Table 8 (continued). Summary Statistics for Anthropometric and Metabolic Parameters.
Variable
Week
Almond
Carbohydrate
% change =
Absolute change =
LSM (SE)
(CHO)
week 24 - week 0
week 24 - week 0
(n = 28)
LSM (SE)
week 0
(n = 29)
Almond CHO
CHO
Almond
Ketones
0
0.11 (0.04)
0.10(0.04)
+250
0
+0.25
0
(mmol/L)
24
0.36 (0.05)
0.10(0.05)
HgbAlc

0

(%)

24

'O

8.62 (0.24)
(n = 20)
7.34 (0.28)
(n = 20)

8.62 (0.23)
(n=21)
7.55 (0.23)
(n = 21)

-14.85

-12.41

-1.28

-1.07

P valuet
group
x time
effect

P valuef
time
effect

0.0230*

0.0083*

0.6713

<0.0001*

f All outcome variables were adjusted for their baseline values in the models. P values are based on mixed models with an
autoregressive covariance structure of order one, with all time points (weeks 0, 8, 16 and 24) included in the model.
* Indicates statistically significant difference between groups.
LSM = least squares means
SE = standard error

Table 9. Weight Results Controlling for Diabetes, Hypertension or Gender
Outcome Adjustment
Wk
Almond
CHO
% change =
variable
variable
LSM (SE)
LSM (SE)
wk 24 - wk 0
wk 0
(AV)
Almond CHO

Weight

o\
o

Diabetes

Absolute change
= wk 24 - wk 0

P valuef

Almond

Group
AV
x time
x time
effect
effect
0.0067* 0.2936

CHO

240.30(2.82) 238.69(2.78) -17.54
-10.83 -42.14
-25.84
198.16(3.14) 212.85(3.02)
Weight
Hypertension
240.98(2.77) 239.48(2.75) -17.59
-10.83 -42.39
-25.93 0.0065* 0.8601
198.59(3.15) 213.55(2.99)
Weight
Gender
241.17(2.77) 239.48(2.72) -17.59
-10.79 -42.42
-25.84 0.0062* 0.7351
198.75(3.13) 213.64(3.00)
t The outcome variable (weight) was adjusted for its baseline value in all models. P values are based on mixed models with
an autoregressive covariance structure of order one, with all time points (weeks 0, 8, 16 and 24) included in the model.
* Indicates statistically significant difference between groups.
LSM = least squares mean
SE = standard error
Wk = week
CHO = carbohydrate
0
24
0
24
0
24

Table 10. Change in Plasma Lipids from Week 0 to Weeks 8, 16 and 24 in the Almond Group

Week 0 (n = 28)
Plasma lipids'
Total cholesterol (mg/dl)
HDL (mg/dl)
Triglycerides (mg/dl)
Total cholesterol:HDL

o\

Week 8 (n = 26)

Week 16 (n = 23)

194.55 ±7.67
175.5± 10.45
169.47 ±8.60
44.41 ±1.92
42.31 ±1.44
42.52 ± 1.85
178.33 ± 19.11
161.46 ± 19.74
137.48 ± 15.56
4.65 ± 0.23
4.20 ± 0.24
4.06 ±0.19
VLDL-C (mg/dl)
40.52 ±3.23
37.88 ±3.91
36.61 ±3.26
LDL-C (mg/dl)
97.85 ±5.01
86.88 ±5.86
81.48 ±4.87
HDL-C (mg/dl)
31.93 ± 1.68
30.73 ± 1.28
29 ± 1.37
LDL-C :HDL-C
3.17 ± 0.16
2.89 ±0.19
2.91 ± 0.20
VLDL-TG (mg/dl)
118.41 ±15.57
106.42 ± 15.21
87.35 ± 11.75
LDL-TG (mg/dl)
29.81 ±2.02
27.54 ± 1.75
26.65 ± 1.86
HDL-TG (mg/dl)
11.11 ±0.33
10.58 ±0.64
10.48 ±0.65
aTo convert from mg/dl to mmol/1, divide cholesterol values by 38.67 and triglyceride values by 88.54.
Note: Data are means ± SEM
SEM = standard error of the mean

Week 24 (n = 22)
170.41 ±9.50
43.54 ± 1.92
123.36 ± 18.60
3.90 ±0.22
31.27 ±3.98
83.18 ±6.73
30.72 ± 1.82
2.86 ±0.29
77.23 ± 14.31
24.09 ± 1.33
9.95 ± 0.64

Table 11. Change in Plasma Lipids from Week 0 to Weeks 8, 16 and 24 in the Carbohydrate (CHO) Group
Week0(n = 29)
Week 8 (n = 27)
Week 16 (n = 24)
Week 24 (n = 24)

ON

to

Plasma lipidsa
192.07± 5.97
Total cholesterol (mg/dl)
215.75 ±8.16
197.87 ±7.62
HDL (mg/dl)
46.28 ±2.01
49.58 ±2.32
44.63 ± 1.97
Triglycerides (mg/dl)
203.25 ±20.86
177.26 ±20.29
138.58 ± 13.54
Total cholesterol:HDL
4.13 ±0.21
4.77 ± 0.25
4.50 ±0.23
44.93 ±4.16
VLDL-C (mg/dl)
48.00 ±4.59
40.75 ± 3.40
LDL-C (mg/dl)
105.43 ±5.53
92.78 ± 4.02
99.25 ± 5.47
32.85 ± 1.85
HDL-C (mg/dl)
32.87 ± 1.69
36.88 ±2.20
LDL-C :HDL-C
3.41 ±0.23
3.03 ± 0.20
2.88 ±0.20
VLDL-TG (mg/dl)
135.83 ± 15.37
120.18 ± 16.99
87.17 ± 10.47
LDL-TG (mg/dl)
33.47 ± 1.70
29.15 ± 1.39
29.42 ±2.01
HDL-TG (mg/dl)
12.13 ±0.43
12.04 ±0.49
11.79 ±0.80
aTo convert from mg/dl to mmol/1, divide cholesterol values by 38.67 and triglyceride values by 88.54.
Note: Data are means ± SEM
SEM = standard error of the mean

200.33 ±7.21
51.5 ±2.48
135.79 ± 10.78
4.21 ±0.23
39.21 ±3.24
98.67± 4.27
38.21 ±2.13
2.74 ±0.17
82.33 ± 8.07
28.17± 1.55
11.62 ±0.59

Table 12. Summary Statistics for Plasma Lipids
Week
Almond
Carbohydrate
Variable
% change =
Absolute change = P valuef P valuef
LSM (SE)
(CHO)
week 24 - week 0
week 24 - week 0 group
time
(n = 28)
LSM (SE)
week 0
x time
effect
(n = 29)
CHO
effect
Almond
Almond CHO
TC (mg/dl)
0
198.25 (8.11) 212.70 (8.26) -11.66
-6.98
-23.12
-14.84
0.8630
<.0001*
24
175.13 (8.63) 197.86 (8.50)
HDL (mg/dl)
0
+8.62
45.73 (1.40)
45.29 (1.39)
+0.24
+0.11
+3.94
0.4983
0.7848
24
45.40(1.44)
49.67(1.28)
TG (mg/dl)
0
192.07(18.44) 189.93(18.78) -31.10
-19.36
-59.74
-36.77
0.5672
0.0024*
24
132.33(19.85) 153.16(19.46)
TC:HDL
0
4.65 (0.22)
4.77 (0.23)
-11.83
-11.74
-0.55
-0.56
0.7075
0.0022*
24
4.10(0.25)
4.21 (0.25)
VLDL-C
0
43.36 (3.76)
45.52 (3.70)
-22.86
-9.16
-9.91
-4.17
0.4525
0.0386*
(mg/dl)
24
33.45 (4.03)
41.35(3.91)
LDL-C
0
98.18(5.16)
105.38 (5.07) -13.96
-9.85
-13.71
-10.38
0.7758
0.0001*
(mg/dl)
24
84.47(5.55)
95.00 (5.37)
HDL-C
0
32.17 (1.52)
33.41 (1.48)
-3.11
+11.28 -1.0
+3.77
0.1836
0.2004
(mg/dl)
24
31.17(1.57)
37.18 (1.40)
3.24 (0.20)
LDL-C: HDL-C 0
3.35 (0.19)
-10.19
-18.21
-0.33
-0.61
0.7934
0.0268*
24
2.91 (0.22)
2.74 (0.21)
VLDL-TG
0
129.14(14.38) 126.07(14.13) -36.14
-23.46
-46.67
-29.58
0.5203
0.0028*
(mg/dl)
24
82.47 (15.50) 96.49(15.02)
LDL-TG
0
30.00 (1.67)
33.41 (1.64)
-16.33
-14.82
-4.90
-4.95
0.9135
0.0003*
(mg/dl)
24
25.0 (1.79)
28.46 (1.73)
HDL-TG
0
11.25(0.55)
12.03 (0.54)
-9.87
-1.11
-3.57
-0.43
0.9070
0.5140
(mg/dl)
24
10.14(0.62)
11.60 (0.59)
f All outcome variables were adjusted for their baseline values in the models. P values are based on mixed models with an
autoregressive covariance structure of order one, with all time points (weeks 0, 8, 16 and 24) included in the model,
indicates statistically significant difference between groups. LSM = least squares mean; SE = standard error

Table 13. Change in Blood Pressure from Week 0 to Week 24 in the Almond and Carbohydrate (CHO) Group
Almond group
CHO group
Week 0 (n = 28)
Week 24 (n = 22)
Week 0 (n = 29)
Week 24 (n = 24)
Systolic blood pressure (mmHg)
144.14 ±3.24
135.55 ±3.72
135.28 ±4.25J
130.2 ±4.78tt
Diastolic blood pressure (mmHg)
77.93 ±2.02
77.11 ±2.66
71.67 ±2.30f
71.22 ±2.15
tp< 0.05, for the contrasts from week 0 to 24 for the changes over time within groups
Jp< 0.05, for the contrasts from week 0 to 24 for the changes over time between groups
Note: Data are means ± SEM
SEM = standard error of the mean

On

Table 14. Summary Statistics for Blood Pressure
Variable
Week
Almond
Carbohydrate
LSM (SE)
(CHO)
LSM (SE)

% change =
week 24 - week 0
week 0

Absolute change =
week 24 - week 0

P valuet
P value*!*
group x
time
time effect effect

Almond
CHO Almond
CHO
Systolic blood 0
144.80 (3.44) 134.94 (3.47) -10.27
-0.01
-14.87
-0.97
0.2705
0.0506*
pressure
24
129.93 (4.13) 133.97 (3.90)
(mmHg)
Diastolic
0
78.01 (1.86)
76.83 (1.88)
-8.15
-7.86
-6.36
-6.04
0.4183
0.0371*
blood
24
71.65 (2.36)
70.79 (2.19)
pressure
(mmHg)
f All outcome variables were adjusted for their baseline values in the models. P values are based on mixed models with an
autoregressive covariance structure of order one, with all time points (weeks 0, 8, 16 and 24) included in the model.
* Indicates statistically significant difference between groups.
LSM = least squares means
SE = standard error

Table 15. Summary of Results of Questionnaire Scores Related to Satiety
Question #1: How strong is your wish to eat? (0 = Very weak; 10 = Very strong)
1 to 2 hours after:

Breakfast

Lunch

Dinner

Group x time
effect:

P value = 0.6412

P value = 0.7689

P value = 0.4044

LSM ± SE

LSM ± SE

4.7 ± 0.6
3.8 ±0.6
3.9 ±0.6
3.9 ±0.6

3.7 ±0.5
3.9 ±0.5
4.2 ±0.6
4.3 ±0.6

3.8 ±0.7
4.4 ± 0.7
4.2 ± 0.7
4.3 ±0.7

3.9 ±0.6
4.3 ±0.6
3.4 ± 0.6
3.6 ± 0.6

3.2 ±0.5
3.6 ±0.6
3.3 ±0.6
3.1 ±0.5

4.0 ±0.7
5.0 ±0.7
4.8 ±0.7
3.2 ±0.7

Group

Week LSM ± SE

Almond
Almond
Almond
Almond

0

CHO
CHO
CHO
CHO

8
16
24
0

8
16
24

Question #2: How hungry do you feel? (0 = Not hungry at all; 10 = Hungry as I have
ever felt)
1 to 2 hours after:

Breakfast

Lunch

Dinner

Group x time
effect:

P value =0.3310

P value = 0.8053

P value = 0.5562

LSM ± SE

LSM ± SE

4.6 ± 0.6
3.4 ± 0.6
3.5 ±0.6
4.2 ±0.6

3.7 ±0.5
3.4 ±0.5
4.2 ±0.6
3.9 ±0.6

3.7 ±0.6
3.9 ±0.6
4.0 ± 0.6
4.0 ±0.6

3.3 ±0.6
4.0 ±0.6
3.3 ±0.6
3.6 ± 0.6

2.8 ±0.5
3.4 ± 0.6
3.4 ± 0.6
3.3 ±0.5

3.0 ±0.6
4.2 ±0.6
3.9 ±0.6
3.0 ±0.6

Group

Week LSM ± SE

Almond
Almond
Almond
Almond

0

CHO
CHO
CHO
CHO

0

8
16
24

8
16
24
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Table 15 (continued). Summary of Results of Questionnaire Scores Related to Satiety
Question #3: How full do you feel? (0 = Not full at all; 10 = Very full)
1 to 2 hours after:

Breakfast

Lunch

Dinner

Group x time
effect:

P value = 0.9150

P value = 0.0516

P value = 0.0538

Group

Week LSM ± SE

LSM ± SE

LSM ± SE

Almond
Almond
Almond
Almond

0
8
16
24

5.1 ±0.5
5.7 ±0.5
4.7 ± 0.6
4.5 ± 0.6

6.0 ± 0.5
5.7 ±0.5
5.2 ±0.6
4.8 ±0.6

6.5 ± 0.5
5.8 ±0.5
5.8 ±0.6
5.1 ±0.6

CHO
CHO
CHO
CHO

0
8
16
24

5.8 ±0.6
6.2 ± 0.6
5.5 ±0.6
5.8 ±0.5

5.7 ±0.5
6.6 ± 0.6
7.0 ±0.6
6.7 ±0.5

5.8 ±0.5
6.9 ±0.6
6.8 ± 0.6
7.0 ±0.5

CHO = carbohydrate
LSM = least squares mean
SE = standard error
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Table 16. Summary of Results of Questionnaire Scores Related to Satisfaction
Question #4: How satisfied are you with the texture of the diet? (0 = Not satisfied at all;
10 = Very satisfied)
1 to 2 hours after:

Breakfast

Lunch

Dinner

Group x time
effect:

P value = 0.5420

P value = 0.5371

P value = 0.1640

LSM ± SE

LSM ± SE

6.7 ±0.6
6.5 ± 0.5
6.9 ±0.6
6.4 ±0.6

6.7 ±0.5
6.6 ± 0.5
7.1 ±0.5
6.8 ± 0.5

8.0 ±0.5
6.7 ±0.5
7.0 ±0.5
6.7 ±0.5

7.1 ±0.6
6.4 ± 0.6
7.1 ±0.6
7.8 ±0.6

7.8 ±0.5
7.7 ±0.5
7.1 ±0.5
7.8 ±0.5

7.9 ±0.5
7.8 ±0.5
7.4 ±0.5
8.0 ±0.5

Group

Time LSM ± SE

Almond
Almond
Almond
Almond

0

CHO
CHO
CHO
CHO

8
16
24
0

8
16
24

Question #5: How satisfied are you with the taste of the diet? (0 = Not satisfied at all; 10
= Very satisfied)
1 to 2 hours after:

Breakfast

Lunch

Dinner

Group x time
effect:

P value = 0.2184

P value = 0.3789

P value = 0.2779

LSM ± SE

LSM ± SE

7.0 ±0.5
7.5 ± 0.4
7.9 ±0.5
7.5 ±0.5

6.9 ±0.5
7.6 ±0.4
7.5 ±0.5
7.4 ±0.5

8.2 ±0.5
7.0 ±0.4
7.4 ±0.5
7.1 ±0.5

8.2 ±0.5
7.5 ±0.5
7.5 ±0.5
8.4 ±0.5

8.1 ±0.4
7.7 ±0.5
7.5 ±0.5
8.0 ±0.4

8.2 ±0.4
7.9 ±0.4
8.1 ±0.5
8.0 ±0.4

Group

Time LSM ± SE

Almond
Almond
Almond
Almond

0

CHO
CHO
CHO
CHO

8
16
24
0

8
16
24

CHO = carbohydrate
LSM = least squares mean
SE = standard error
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CHAPTER 5
DISCUSSION
A. Anthropometric Parameters
This randomized study found that patients consuming almonds experienced a
statistically significant reduction in weight, BMI, waist circumference and fat mass
(Figures 2-5, respectively) than patients consuming complex carbohydrates (CHO)
during participation in the 24-week D & CVRRP. A 75% greater reduction in weight,
(-18% vs. -10%), 65% greater reduction in BMI (-18% vs. -11%), 52% greater
reduction in waist circumference (-14% vs. -9%), and 56% greater reduction in fat mass
were observed in the almond group as compared to the CHO group. This result is
inconsistent with those obtained in previous studies which found equivalent weight loss
using a moderate-fat versus low-fat hypocaloric diet for weight loss in overweight
adults (Golay et al., 1996; McManus, Antinoro, & Sacks, 2001). Moderate weight loss
of 5 to 10% has been shown to provide benefits for obese patients by amelioration of
concurrent disease states, i.e. hypertension, diabetes, dyslipidemia (Blundell, Lawton,
Cotton & Macdiarmid, 1996). In this study, seventy-three percent of the patients in the
almond group achieved at least a 10% weight loss, compared to only 54% in the CHO
group.
In light of the group imbalance of patients with a diagnosis of hypertension at
baseline, it may have been possible that diuretic effects influenced the difference noted
in the weight loss that was observed between the groups. An investigation into the total
body water content between the groups from the bioelectrical impedance analysis
results failed to support this theory.
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B. Cardiovascular Risk Factors
In the context of diminishing cardiovascular risk, the decrease in BMI, waist
circumference and fat mass were more pronounced in the almond group as compared to
the CHO group. Additionally, both groups experienced improved blood pressure
control over time. There were a higher percentage of patients in the CHO group
categorized as having hypertension at baseline. A greater reduction in systolic blood
pressure was observed in the almond group, however there was no statistically
significant difference in either systolic or diastolic blood pressure between the groups.
Patients in both groups experienced reductions in their anti-hypertensive medications
during the 24-week study. Thus, it is possible that the smaller reduction in systolic
blood pressure noted within the CHO group may have been a reflection that the patients
in the CHO group were on anti-hypertensive medications that led to better blood
pressure control at baseline.
Some investigators have found favorable changes in lipids induced by weight
reduction (Nicklas et al., 1997; Cordero-Maclntyre et al., 2000), whereas others have
found no effects or deterioration in lipid indices (Weinsier et al., 1992), with the most
variable lipid response being HDL-C. Our study was unable to demonstrate a
statistically significant difference between the groups for any lipid parameter that was
measured. Longitudinal research studies performed among the obese free-living
population are challenged by the inability to control variables that impact plasma lipid
concentrations, i.e. energy restriction itself, exercise and biologic/phenotype variability.
Others have shown that HDL-C decreases during active weight loss but increases after
the termination of dieting when body weight stabilizes (Datillo & Kris-Etherton, 1992;
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Johnson et al., 1982). During acute weight reduction, tissue concentrations of
lipoprotein lipase have been found to decrease by 50% to 80% (Taskinen & Nikkila,
1979), resulting in a reduction in TG-rich lipoprotein synthesis, impaired VLDL-C
catabolism, and a diminished transfer of lipids to HDL-C with resulting decreased
HDL-C concentrations.
Zambon et al. (1999) found that LDL-C decreased significantly in a group of
obese adults consuming hypocaloric diets enriched in oleic acid (MUFA) and complex
carbohydrates. However, with an equal magnitude of weight loss, HDL-C increased
significantly in the high MUFA group and a decreased level was observed in the
complex carbohydrate group (Zambon et al., 1999). Our study found both groups had a
statistically significant decrease in LDL-C over time (Figure 6), however as noted
above, no statistically significant difference was found between the groups. It is worth
noting that the almond group experienced a 56% greater reduction in TC (-12% vs. 7%),
32% greater reduction in LDL-C (-14% vs. 10%), and a 62% greater reduction in TG (31% vs. 19%). However, with an unequal magnitude of weight loss, HDL-C increased
in the CHO group and decreased in the almond group (Figure 7). In light of the lesser
reduction in TC, LDL-C and TG within the CHO group, there may have be a
compensatory need to upregulate HDL-C synthesis.
Diminishing cardiovascular risk occurred in both groups. A 12% reduction in
the TC:HDL ratio was observed in both groups (Figure 8). The CHO group
demonstrated an increase in HDL-C at week 24 from baseline, possibly as an outcome
of the lower magnitude of weight reduction or the achievement of weight stability
approaching week 24. Participants in the almond group were found to have greater
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decreases in TC, VLDL-C, LDL-C, and LDL-TG in the presence of a higher magnitude
of weight loss, whereas research participants in the CHO group showed a greater
decrease in HDL-C and HDL-TG. Again, no statistically significant difference was
found between the groups in any of the aforementioned lipid parameters.
C. Further Comment
The unprecedented difference in weight loss and anthropometric parameters was
not predicted due to the study design featuring a matched protein and total calorie
intake. Neither gender, presence of diabetes mellitus nor hypertension were found to
influence the difference in degree of weight loss found between the two groups.
The development of statistically significantly higher ketone levels among the
almond group participants is consistent with the nature of very low calorie diets that
feature high levels of protein and fat but little carbohydrate. The increased production
of ketones (acetoacetic acid and 3-beta-hydroxybutyric acid) may have exceeded the
levels in which the tissues could oxidize the fat intermediates as an energy source. Thus
some calories could have been lost through ketonuria. Additionally, the absorption of
the fat within the almond may be compromised by the fiber content of the nut. The 84
grams of almonds supplied 485 kcal of energy daily, of which 387 calories are derived
from fat. Others have anecdotally noted that unexpected weight loss occurs in
controlled feeding trials featuring the inclusion of almonds under isocaloric conditions
(Sabate, Communication). Thus, there may have been an imbalance of total utilizable
calories between the groups.
The change in the hormonal milieu that occurs in the presence of high fat diets
may have favorably improved the utilization of fat as an energy source versus
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enhancement of adiposity. Others have found a greater improvement of fasting plasma
glucose, insulin and IGR using a low carbohydrate diet enhanced with monounsaturated
fat (Golay et al., 1996). Similarly, the almond group demonstrated a 69% greater
decrease of plasma insulin (-58% vs. 29%), a 42% greater decrease of glucose (-20%
vs. -14%) and a 60% greater decrease in the IGR (-50% vs. -30%) than the CHO group
(Figures 9-11, respectively). Thus there may have been effects on how muscle and fat
cells uptake fat in the context of a high fat diet, and the rate at which they bum more fat
with resulting higher ketone levels. Or, perhaps the almond as a source of oleic acid
may contribute to improved beta-cell efficiency.
Among the patients with diabetes mellitus in both groups, HgbAlc levels
favorably decreased over time. However, no statistically significant difference was
found between the groups. Diabetic patients in both groups experienced dramatic
reductions, if not elimination, of their diabetes medications during the 24-week study.
It is important to note that the greater reduction in insulin and glucose levels observed
in the almond group compared to the CHO group did not correlate with the magnitude
of change in HgbAlc in the almond as compared to the CHO group (-15% vs. -12%).
Thus, it is possible that the diabetic patients in the almond group were weaned off of
their diabetes medications at a faster rate than the CHO group, thus conferring a degree
of clinical relevance.
Previous research has shown preferential use and oxidation of carbohydrate after
a meal and the ability of carbohydrate to stimulate satiety more than fat (Blundell et al.,
1996; Mayer, 1972). The macronutrient mix and the higher fiber intake consumed by
research participants in the CHO group should have theoretically produced a higher
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level of satiety. In the present study, self-reported hunger 1 to 2 hours after meals using
a 10-point scale did not significantly differ between or within the groups at baseline or
at weeks 8, 16 and 24. High carbohydrate intakes may affect metabolic rate and energy
expenditure via the thermic effect of food to a greater degree than fat under isocaloric
conditions, but it is unknown to what degree these factors influence satiety and
compliance in the obese under hypocaloric conditions.
The mechanisms leading to overeating and to the obese state are multifactorial
and occur over prolonged periods of time. The preponderance of previous experimental
studies evaluating fuel oxidation, satiety and overeating have featured only short study
periods (Willett, 1998). However, these studies universally promote the intake of low
energy-dense foods over high energy-dense foods containing fat. Translation of these
research findings into the complexities of food consumption patterns have been
challenged by this study’s findings. The habitual underreporting of food intake among
the obese population has been well documented. The obese patient receiving guidelines
on how to select appropriate portion sizes of complex carbohydrates may be
subconsciously translated into an unintended surplus of calories. The types of complex
carbohydrates that are available at restaurants, fast food chains or in the patient’s social
environment, and their ability to prepare them according to specific guidelines, may be
impractical for public health focused clinicians to expect from patients over a prolonged
period of time. In this study, it appears that the critical influence on total calorie intake
was not the metabolic differences between macronutrients or malabsorption, but
perhaps hormonal, environmental and behavioral factors.
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One of the primary complaints among obese patients participating in medically
supervised weight reduction programs that incorporate a liquid protein sparing
formulation is the lack of chewing. Thus, motivation and compliance are difficult to
sustain in long-term weight reduction programs and research studies. In this study,
research participants were encouraged to consume “crunchy” complex carbohydrates,
i.e. popcorn, whole wheat crackers, etc. to parallel the chewing experiences of the
almond consumers.
Upon weekly questioning, patients reported satisfaction with their randomized
group assignments and food options. Research participants in the almond group
enjoyed the convenience of the almonds. Questions #1 and #2 on the questionnaire led
to unequivocal results. However, in response to question #3 “How full do you feel”,
borderline significance was found after lunch and after dinner between the two groups
over time. It appeared that the almonds were losing some of their influence on satiety
over time, whereas the CHO group was reporting an increasing sense of fullness over
time. It can be speculated that the statistically significant difference in the magnitude of
weight loss between the groups over time may have altered plasma leptin levels which
could influence satiety, or perhaps the compliance among the CHO group may have
diminished over time leading to larger than prescribed portion sizes of complex
carbohydrates and/or intake of non-prescribed high protein foods, i.e., meat, fish,
poultry. Participants in the CHO group reported satisfaction with their variety of food
choices for meal and snack planning. Although there were two varieties of almonds
with equivalent nutrient values (dry roasted and raw) available to reduce monotony,
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over 80% of the almond group participants developed a strong preference for dry
roasted almonds within two weeks of study participation.
The dietary protocol featured non-traditional weight reduction foods, i.e.
popcorn, almonds, hence the foods may have been spared from monotony effects.
Others (Miller et al., 2000) have found chocolate and potato chips, representing highly
palatable, high-fat, energy dense snacks to be resistant to monotony effects over several
weeks of daily consumption. Similarly, we found that the daily consumption of
almonds and complex carbohydrates led to successful weight loss in both groups, with
no dropouts in either group due to discontent with their random group assignment.
D. Limitations
The study was limited by relying on the self-reported daily food intake and
exercise in the diaries of the study participants. Self-reports of dietary intakes and
lifestyle behaviors may have been influenced through researcher expectancies and
social desirability.
Possible confounding may have occurred due to the specific vitamin, mineral
and phytochemical content in complex carbohydrates versus almonds. However, both
groups were given the same wash out and run-in period of vitamin/mineral
supplementation to minimize these effects.
Additional study limitations included representation, compensatory rivalry and
resentful demoralization. The ethnic and socioeconomic mixture in the capture area of
COH may not be representative of the general adult obese population throughout the
US. Also, study participants were in contact with each other during weekly clinic visits
and group classes, hence discussed differences in dietary interventions. Participants
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receiving “less desirable” treatments may have been motivated to increase their weight
loss effort. Resentful demoralization of participants receiving “less desirable”
treatments could have played out in the weekly educational sessions or clinic visits, and
these participants may have lost motivation. However, the investigator was in
attendance at weekly clinic visits and group classes to provide ongoing encouragement
to provide a sense of neutrality among the participants.
Lastly, the study explored the effects of only one type of tree nut versus a mixed
variety of tree nuts, in a small sample size. Additional studies are warranted with larger
sample sizes and using a variety of mixed tree nuts.
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Figure 2. Change in Weight Over Time in the Two Study Groups (Note: Data are presented as least squares means and
95% Cl)
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Figure 3. Change in Body Mass Index Over Time in the Two Study Groups (Note: Data are presented as least squares
means and 95% Cl)
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Figure 4. Change in Waist Circumference Over Time in the Two Study Groups (Note: Data are presented as least squares
means and 95% Cl)
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Figure 5. Change in Fat Mass Over Time in the Two Study Groups (Note: Data are presented as least squares means
and 95% Cl)
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Figure 6. Change in Low Density Lipoprotein Cholesterol (LDL-C) Over Time in the Two Study Groups (Note: Data are
presented as least squares means and 95% Cl)
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Figure 7. Change in High Density Lipoprotein Cholesterol (HDL-C) Over Time in the Two Study Groups (Note: Data
are presented as least squares means and 95% Cl)
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Figure 8. Change in Total Cholesterol:High Density Lipoprotein (Total ChohHDL) Ratio Over Time in the Two Study
Groups (Note: Data are presented as least squares means and 95% Cl)
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Figure 9. Change in Insulin Over Time in the Two Study Groups (Note: Data are presented as least squares means and
95% Cl)
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Figure 10. Change in Glucose Over Time in the Two Study Groups (Note: Data are presented as least squares means and
95% Cl)

oo

Figure 11. Change in Insulin:Glucose Ratio Over Time in the Two Study Groups (Note: Data are presented as least
squares means and 95% Cl)

CHAPTER 6
SUMMARY AND CONCLUSIONS
A. Summary
This randomized study found that patients consuming almonds experienced a
statistically significant reduction in weight, BMI, waist circumference and fat mass
than patients consuming complex carbohydrates (CHO) during participation in the 24week D & CVRRP. Seventy-three percent of the patients in the almond group achieved
at least a 10% weight loss, compared to only 54% in the CHO group.
Improvement in metabolic parameters linked to insulin sensitivity was found
over time in both groups and decreased HgbAlc levels were observed. The disparity
between the increased insulin sensitivity observed in the almond group as measured by
the IGR, and the similar degree of decrease in HgbAlc in both groups, leads one to
speculate on the possible differences between the groups in the rates of weaning of
patients from their pre-study diabetes medications.
An overall improvement in cardiovascular risk was found in both groups,
however, the longitudinal study design in combination with the small sample size was
unable to detect a statistically significant difference between the groups on any of the
lipid parameters that were measured. Both groups experienced improved blood
pressure control over time. Although there was no statistically significant difference in
blood pressure reduction between the groups, anti-hypertensive medications were
greatly reduced or eliminated in patients in both groups during the 24-week study.
Further, this study found both groups had a statistically significant decrease in TC,
LDL-C and TG over time, with greater reductions observed in the almond group.
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However, with an unequal magnitude of weight loss, HDL-C increased 11% in the
CHO group and decreased 3% in the almond group. The degree of improvement in the
LDL-C:HDL-C was not significantly different between the groups, and both groups
were in the direction of diminishing cardiovascular risk. Thus, the lower magnitude of
weight reduction observed in the CHO group or the achievement of weight stability
may have contributed to the overall increase in HDL-C. The lack of increase in HDL-C
in the almond group as compared to the CHO group may not have any overall adverse
metabolic effects in the context of an equivalent diminished lipid burden.
B. Implications of Findings
From a practical public health point of view, if clinicians are capable of
sustaining motivation and adherence within their obese sector, a successful diet plan
could incorporate moderate amounts of monounsaturated fat as long as anthropometric
change favorably and plasma lipids do not deteriorate. Our findings support the use of
almonds, as a source of MUFA, as a component of a hypocaloric diet in obese patients,
as an alternative to conventional low-fat dietary foods. An almond-enriched
hypocaloric diet may have unique beneficial effects compared with the conventional
high carbohydrate low-fat diet approach for the treatment of the atherogenic metabolic
risk profile (Krauss, 2001), and may prevent the conversion to more deleterious LDL-C
subclasses. The trading of carbohydrates for MUFAs during weight reduction may be a
consideration in future public health recommendations for the obese population. Many
obese people enrolled in medically supervised weight control programs may find that
the ingestion of almonds may be more acceptable than severe restriction of dietary fat
over long periods of time. However, these results call for further study in larger
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numbers of subjects and using a variety of nuts. The use of almonds or mixed nuts to
prevent the recidivism after successful weight reduction also deserves consideration, as
we must keep in sight the potential detrimental effects associated with weight cycling
(Prentice et ah, 1992; Williamson, 1996).
C. Future Research
Additional testing on plasma to evaluate changes in apolipoproteins A-l, B-100
and E, Lp(a), PAI-1-1, C-Peptide, nitric oxide (NO), magnesium and leptin would be
valuable to complement and strengthen the study’s findings. Following is a summary of
the justification for analytical tests that can help elucidate further benefits of almond
and complex carbohydrate enriched diets during medically supervised weight reduction.
1. Plasma Free Fatty Acids
The evaluation of fasting plasma free fatty acids is imperative to help
explain the differences in HgbAlc levels, glucose, and insulin levels among the
research participants with type 2 diabetes mellitus and/or metabolic syndrome. Insulin
resistance, hepatic glucose production and abnormal lipid production in the liver are
sensitive to fasting plasma free fatty acids and evolution of the metabolic syndrome
(Reaven, 1995). The adipocyte is a critical mediator between insulin and liver glucose
output, and evidence that free fatty acids suppress skeletal muscle glucose uptake and
insulin secretion from the beta cell supports the overall central role of the adipocyte in
the regulation of glycemia (Bergman & Mittleman, 1998).
2. Apo B-100 and LDL Subclassification
Apo B-100 is the major apoprotein found within VLDL, intermediate
density lipoproteins (IDL) and LDL particles, which to a great extent controls the
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homeostasis of plasma LDL-C (Vrablick, Ceska, & Horinek, 2001). The atherogenic
lipoprotein phenotype (ALP) is characterized by a normal cholesterol concentration
with a moderate increase in plasma TG, a decrease in HDL-C, and a shift in the LDL
size profile towards small dense species (Packard et ah, 2000). Small dense LDL has
properties that enhance its atherogenicity (De Graaf et al., 1991 & Krauss, 1994). At a
given cholesterol level, large numbers of small Apo B-100-containing lipoproteins
(subclass pattern B) are more atherogenic than lower numbers of large apo B-100containing lipoproteins (subclass pattern A) (Veniant et al., 2000 & Packard et al.,
2000).

Due to the significantly different fat content of the dietary interventions, it

would be important to investigate if the research participants in the almond group
starting with subclass pattern A remained subclass pattern A, and that the research
participants in the CHO group starting with subclass pattern A converted to subclass B
during weight reduction.
3. ApoA-I
Apo A-I, the principle apoprotein of plasma HDL, is the major
apoprotein of mesenteric lymph chylomicrons and is actively synthesized by the small
intestine during lipid absorption (Davidson, Magun, Brasitus & Glickman, 1987). The
ratio of apo A-l:apo B-100 is often considered the gold standard which reflects risk of
developing atherosclerosis.
It would be of interest to have apo A-l measurements performed to
elucidate the mechanism by which almonds blunt the drop in HDL-C typically seen
during weight reduction. It may not be deleterious to show a small reduction in HDLC among almond consumers, in contrast to the complex carbohydrate consumers, if
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there is an acceptable apo A-l:apo B-100 ratio in parallel with a greater reduction in fat
mass which occurred among the almond consumers.
4. Apo E
Apo E is a multifunctional protein that can act as a ligand for lipoprotein
receptors (Millar, Lichtenstein, Ordovas, Dolni, Kowoski & Schaefer, 2001).
Interaction between genetics and diet exist with regard to apoE production rates. Diets
that promote hypertriglyceridemia promote increases in small dense LDL-C particles
and reduced synthesis rate of apoE (Pedreno, Hurt-Camejo, Wiklund, Badimon &
Masana, 2000). High levels of apo E help clear triglycerides from plasma and inhibit
platelet aggregation (Pedreno, Hurt-Camejo, Wiklund, Badimon & Masana, 2000). It
would be of great interest to characterize the study population’s relationship of apo E
levels with both apo B-100 levels and levels of PAI-1 (see below) to determine the net
benefit of using almonds or complex carbohydrates under hypocaloric conditions.
5. Lp(a)
Lp(a) is a LDL-like particle that is linked to the development of
atherogenesis and thrombosis.

LP(a) is a cholesterol ester- and apolipoprotein B-

containing particle which differs from LDL by the additional presence of a glycoprotein
termed apolipoprotein(a), homologous to plasminogen (Swertfeger, 2001).

Lp(a)

analysis is necessary to characterize the subjects in each group and to support any
antithrombotic findings caused by the consumption of
influence.
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almonds versus genetic

6. Plasminogen Activator Inhibitor-1 (PAI-1)
The metabolic syndrome can include a procoagulant state which is
known to contribute to the development of atherosclerosis. Dyslipidemia, along with
hyperinsulinemia induces expression of plasminogen activator inhibitor-1 (PAI-1),
which contributes to a prothrombotic state (Pandolfi et ah, 2001).

Others (Lopez-

Segura et al., 1996) have shown that isocaloric diets rich in MUFAs decrease PAI-1
plasma activity, which is accompanied by a parallel decrease in plasma insulin levels.
Due to the accelerated weight loss among the almond group and improvement in
anthropometric parameters, it would be beneficial to characterize any changes in PAI-1
among the study participants.
7. C-Peptide
C-peptide levels serve as a valuable index to insulin secretion. Low Cpeptide levels are to be expected where insulin secretion is diminished or suppressed as
a normal response to exogenous insulin (Horwitz, Kuzuya & Rubenstein, 1976). To
further support the favorable changes in plasma insulin, glucose and IGR, C-peptide is
of importance.
8. Nitric Oxide (NO)
Nitric oxide (NO) performs many useful functions, including regulation
of blood pressure and intercellular signaling. It would be of interest to characterize the
changes in NO due to the different arginine:lysine ratios in the two dietary interventions
as nut protein contains preferentially high levels of arginine, a known dietary precursor
of NO, and low levels of lysine.
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9. Magnesium
Almonds possess several known nutrients that are postulated to provide a
protective effect against coronary heart disease, including magnesium. Thus, it would
be of interest to characterize the effects, if any, of the two dietary interventions on
plasma magnesium levels.
10. Leptin
High-fat meals reduce 24-hour circulating leptin concentrations under
isocaloric diet conditions. Some investigators have previously reported that adipocyte
glucose utilization is involved in insulin-induced leptin secretion in vitro. However,
there is a nocturnal increase of leptin that is related to the insulin response to meals.
High fat meals, which induce smaller insulin and glucose responses, may produce lower
leptin concentrations than low fat meals. Consumption of high fat meals result in
lowered 24- hour circulating leptin concentrations, which may be a consequence of
decreased adipocyte glucose metabolism. It would be of interest to characterize the
effects under hypocaloric diet conditions.
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Registration Procedures

1.

Registration for this study must be made through the Department of
Biostatistics office at the City of Hope between the hours of 8:30 a.m. to
4:30 p.m., Monday through Friday (except holidays).

2.

Patients must sign a COH approved Informed Consent prior to registration.

3.

The investigator must confirm that the patient meets all inclusion and
exclusion eligibility criteria.

If the patient qualifies, the investigator will call the Department of Biostatistics (626)
359-8111 ext. 62468 to complete the registration/randomization procedure and receive
the patient’s Group assignment and study ID number.
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Daily Complex Carbohydrates
Select any one of the following combinations on a day-to-day basis
15
15
15
15

Triscuit crackers + 1 V2 cups boiled frozen peas
Triscuit crackers + 1 cups boiled frozen com
Triscuit crackers + 6 cups air-popped popcorn
Triscuit crackers + 7 ounce baked potato

1
1
1
1

cup boiled rice + 1
cup boiled rice + 1
cup boiled rice + 6
cup boiled rice + 7

1
1
1
1

14
14
14
14

14 cups boiled frozen peas
V2 cups boiled frozen com
cups air-popped popcorn
ounce baked potato

cup boiled pasta + 1
cup boiled pasta + 1
cup boiled pasta + 6
cup boiled pasta + 7

14 cups boiled frozen peas
14 cups boiled frozen com
cups air-popped popcorn
ounce baked potato
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General Dietary Guidelines
DAILY INTAKE:
HMR 70 Plus Formula: You must take
packets of HMR 70 Plus formula per
day.
• Taking all formula and vitamin/mineral supplements is imperative to provide
enough nutrients to maintain optimal nutritional status. Lean body mass can be
depleted without adequate formula and vitamin/mineral supplement intake.
• Prepare formula by using a blender, shaker, whisk or fork. For best results, pour 6
fluid ounces of cold water into a pint container. Empty contents of formula packet
into the cold water. Immediately mix with a fork or shake for 15 seconds until
product is dissolved. (Do not use blender or shaker with carbonated beverages). If
using a blender, leave lid slightly ajar and use quick pulses to minimize foaming.
Scrape the sides of the blender to ensure complete use of the product. Be careful
not to over blend.
• Refer to the recipes for cold drinks, hot drinks, and slushes provided in the program
notebook for added variety.
Salad: You must consume a salad with the following ingredients:
2 cups chopped lettuce (any type)
1 cup chopped celery
1 cup chopped tomato
“Dressing” may contain 2 Tbsp. Lemon Juice or Vinegar and/or pepper
Fluids: You must take a minimum of two quarts of noncaloric fluids per day in addition
to the formula.
• Taking the recommended amount of fluids is essential to prevent potential
lightheadedness.
• Noncaloric fluids include water, diet soda, coffee, tea, and beverage mixes that
contain artificial sweeteners. Coffee and tea are allowed, although moderation (not
more than the equivalent of four cups per day) is recommended to prevent physical
reactions such as chronic headaches and irritability.
• Alcoholic beverages are not permitted because of the risk of medical complications.
Complex carbohydrate group research participants must additionally consume 2
teaspoons of safflower oil (to prevent gall bladder dysfunction). Complex carbohydrate
intake will be achieved through the intake of a combination of complex carbohydrates.
Examples of daily food combinations may be 15 whole wheat crackers (Triscuits™)
plus one of the following selections for day-to-day variety: 1 'A cup peas, 1 A cup com,
6 cups air-popped popcorn or a 7-ounce baked potato.
Almond group research participants must consume the prescribed 84 grams of
unsalted, dry-roasted, raw or slivered almonds.
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Diabetes and Cardiovascular Risk Reduction (D&CVRR)
Program General Information Sheet/Contract
This General Information Sheet/Contract must be read completely and
signed prior to entrance into the Diabetes and Cardiovascular Risk Reduction
Program.
Signature on this General Information Sheet/Contract allows you to
attend 8 weeks of the Diabetes & Cardiovascular Risk Reduction
Program. At the end of the 8 weeks, you will be re-evaluated for
continuation in the program. All rules will be strictly reinforced.
Participation in this program is voluntary. No guarantees can be made
with respect to the amount of weight loss you will achieve and the degree
of improvement of health problems. No guarantees can be made with
regards to the duration of permanence of the weight loss.
General Information
To provide individualized care during the program, a thorough medical and
psychological examination is required for clearance to participate in the
program. The following tests will be scheduled:
Gall bladder Ultrasound
Stress test
Lab test
Screening. Appointments will be made by the appointment center by
telephone or mail with the specific dates and locations for these appointments.
On the third week of the program, the physician will order an exercise
evaluation to be done by the physical therapist. Do Not exercise until you
have this evaluation!
Program Duration. You must be willing to commit to the entire 24-month
cycle of the program. The program consists of three phases; Phase 1 & 2
extends for 9 months. Phase 3 will begin immediately for 15 months duration.

Initials:

Date:

Witness’s Initial:

Date:
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Diet. The Protein-Sparing Modified Diet (P.S.M.D.) program for weight reduction is
designed for participants who have health problems known to improve with weight loss.
Such problems include diabetes mellitus, high blood pressure, coronary artery disease,
joint disease, and lung disease.
During the program, participants drink high-protein liquid formulas and one solid meal
per day. The dietitian will determine the dietary portion of the program based upon
recommendations made by the doctor at the initial evaluation prior to the program.
Clinic Appointments. Participants will attend clinic weekly for a brief medical
evaluation by the physician.
Program Schedule. The D&CVRR Program weekly schedule is as follows:
• Clinic - 3:45 PM - 5:30 PM - Measurement of vital signs, weight, blood
ketones and physician visit.
•

Classes 6:00 PM - 7:30 PM

•

Monthly activity:

Laboratory blood work will be drawn and as necessary
Monthly EKG and as necessary
•

Completion of 36 weeks a stress test will be performed

Classes. Participants are required to attend weekly classes:
•
•
•

Nutrition - Provides information to facilitate weight loss and maintenance
Behavior modification - Enables patient to integrate new behavior into their
lifestyle that facilitate weight loss and maintenance
Exercise - Enable patient to develop a safe, effective personalized exercise
plan.

Initials:

Date:

Witness’s Initial:

Date:
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Participant’s Responsibilities
To assure the safety of my health, I agree to:
Attend all scheduled appointments for the duration of the program.
Absences, three consecutive scheduled weekly visits or seven non-consecutive
visits or portions of visits during the entire program is grounds for discharge
from the program. If you cannot attend a weekly session for any reason, please
call the Program Coordinator at (626) 359-8111 ext. 5994.
Consume all of the formula/food prescribed on the diet.
Consume the prescribed amount of non-caloric fluids (2 quarts a day).
Take all medications as prescribed by the physician.
Avoid all use of Rezulin and Avandia, alcoholic beverages, illicit drugs,
coumadin, antidepressants, tranquilizers, amphetamines, or other non
prescription weight-reducing medications.
Report all adverse reactions or side effects to the physician and/or Program
Coordinator at the weekly visits.
Side effects can include sensitivity to cold, dry skin, temporary rashes,
dizziness, lightheadedness, fatigue, diarrhea or constipation, muscle cramps,
bad breath, change in menstrual pattern, temporary hair loss, irregular heart
beats, heart palpitations, and/or excessive hunger.
Unusual side effects which occur in rare cases include numbness in the legs,
loss of muscle strength in the legs, joint pain (gout) and/or gallstones.
Sometimes a participant will find that as they lose weight, they will experience
periods of emotional stress related to the actual weight loss. No guarantees can
be made regarding the type of side effects one may experience.

Initials:

Date:

Witness’s Initial:

Date:
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Special Circumstances
For participants with diabetes mellitus, home blood glucose testing is required.
The diabetic participant must test blood glucose one or more times daily. For
blood glucose less than 60 or greater than 250, call the Physician or Program
Coordinator. The participant also must notify the physician and/or Program
Coordinator whenever he/she experiences light-headedness, perspiration,
trembling and nervousness. These are signs of hypoglycemia (low blood
sugar).
For female participants, the effects of low calorie diet on the fetus are unknown.
If a participant suspects that she is pregnant, she must notify the Physician
and/or Program Coordinator immediately.
For participants with hypertension, participants must notify the Physician
and/or the Program Coordinator if he/she experiences weakness or dizziness
when he/she stands upright. These are signs of hypotension (low blood
pressure).
I understand the following:
I may discontinue participation in the program at any time by providing the
Program Coordinator with verbal or written notification.
During phase 1 & 2 the diagnosis of Diabetes, Hypertension and
Hyperlipidemia will be temporarily managed by D&CVRR Program physician.
During phase 3 the medical management of medical problems related to obesity
will be the responsibility of my primary physician.
I understand completely the general information regarding the program and
agree to comply with the requirements of the City of Hope National Medical
Center Diabetes and Cardiovascular risk Reduction Program.
If at any time I cannot meet the requirements, I will inform the Program
Coordinator who will arrange for my discharge from the program. I will
contact the Program Coordinator or Physicians at (626) 359-8111 ext. 2251 for
any questions or problems that I encounter.

Participant’s Name/Signature

Date

Witness’s Name/Signature

Date
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APPENDIX E
SATIETY AND SATISFACTION QUESTIONNAIRE
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Name
Date

1-2 hours after breakfast

As a participant in the research study, we want to assess your overall satisfaction
with your prescribed diet. Following is a list of statements regarding your appetite
and dietary satisfaction. Please draw a circle at the point on the line to indicate
your current feelings.
How strong is your wish to eat?
0—-1.—2-—3-—4—-5-—6-—7-—8—-9-— 10
Very strong
Very weak

How hungry do you feel?
0
1 -—2—-3—-4—-5—-6-—7-—8—-9-— 10
Hungry as I have
Not hungry
ever felt
at all

How full do you feel?
0-— 1 -—2-—3-—4-—5-—6-—7—-8-—9-— 10
Very full
Not full
at all

How satisfied are you with the texture of the diet?
0-— l -—2-—3-—4—-5—-6-—7-—8—-9-— 10
Very satisfied
Not satisfied
at all

How satisfied are you with the taste of the diet?
0
1 -—2—-3—-4—-5—-6—-7-—8—-9-— 10
Very satisfied
Not satisfied
at all
Comments:
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Name
Date

1-2 hours after lunch

As a participant in the research study, we want to assess your overall satisfaction
with your prescribed diet. Following is a list of statements regarding your appetite
and dietary satisfaction. Please draw a circle at the point on the line to indicate
your current feelings.
How strong is your wish to eat?
0-—1-—2-—3-—4-—5—~6—-7—-8—-9-—10
Very strong
Very weak

How hungry do you feel?
0-—1-—2—-3—-4......5-—6-—7-—8—-9-—10
Hungry as I have
Not hungry
ever felt
at all

How full do you feel?
0-— l -—2—-3-—4-—5-—6-—7—-8-—9-— 10
Very full
Not full
at all
How satisfied are you with the texture of the diet?
0---- 1 -—2-—3—-4—-5-—6-—7-—8-—9-— 10
Very satisfied
Not satisfied
at all

How satisfied are you with the taste of the diet?
0—-1—-2-—3—-4-—5-—6-—7—-8-—9-—10
Very satisfied
Not satisfied
at all
Comments:
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1-2 hours after dinner

Name
Date

As a participant in the research study, we want to assess your overall satisfaction
with your prescribed diet. Following is a list of statements regarding your appetite
and dietary satisfaction. Please draw a circle at the point on the line to indicate
your current feelings.
How strong is your wish to eat?
0—-1 -—2-—3-—4—-5-—6-—7-—8-—9-— 10
Very strong
Very weak

How hungry do you feel?
0-— 1 -—2......3-—4—-5-—6—-7—-8-—9-— 10
Hungry as I have
Not hungry
ever
felt
at all

How full do you feel?
0—-1 -—2-—3
Not full
at all

4—-5—-6-—7-—8-—9-— 10
Very full

How satisfied are you with the texture of the diet?
0—-1 -—2—-3-—4~—5-—6—-7-—8-—9-— 10
Very satisfied
Not satisfied
at all

How satisfied are you with the taste of the diet?
0-— l -—2-—3-—4-—5—-6-—7-—8-—9-— 10
Very satisfied
Not satisfied
at all
Comments:
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APPENDIX F
UNIVERSITY OF SOUTHERN CALIFORNIA LIPID PROCEDURES
(SEPARATION OF LPQ; HDL ANALYSIS USING
PRECIPITATION METHOD)
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SEPARATION OF LPQ (LIPOPROTEIN QUANTIFICATION)
PROCEDURE:
1. Take out ten samples from the rack designated for LPQ analysis.
1.1. Samples should be refrigerated only, not frozen.
2. Number 10 Polycarbonate centrifuge tubes (Beckman -11 x 34 mm).
3. Put 0.5 ml of each sample into the centrifuge tube.
4. Add 0.5 ml 0.9% saline solution into each tube.
4.1. Preparation of 0.9% saline:
4.1.1. Weigh 9 grams of Sodium Chloride (NaCI) and transfer into
1 -liter volumetric flask.
4.1.2. Q.S. to 1000 ml with double deionized (DDI) water. Mix
thoroughly. Stable.
5. Load the ten tubes in the small TL 100.2 rotor.
6. Centrifuge in Beckman TL 100 centrifuge at 65,000 rpm and 5 degrees Centigrade

for 24

hours (Program 6).
7. After 24 hours (22 + or - 2 hours is okay), take out the sample from the centrifuge.
8. Take out the bottom half (0.5 ml) of sample and put into another Polycarbonate centrifuge
tube.
8.1. With a syringe, remove 0.5 ml of the sample (HDL+ LDL) from the bottom of the
tube, taking care to avoid the gel-like precipitate, and holding the syringe plunger steady while
lifting it out of the tube to prevent any mixing.
8.2. Empty the syringe into the corresponding centifuge tube.
8.3. Rinse the syringe 3 times with double de-ionized water.
8.4. Wipe the syringe and plunger with a “Kimwipe” before preceding to the next sample.
9. Transfer the top half (left over in the centrifuge tube) into a COBAS sample cup labeled
“VLDL” with the corresponding ID number.
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10. Store the “VLDL” part in the freezer.
11. To the bottom half of the sample (HDL+ LDL), add 0.5 ml of 30% Sucrose Solution
containing EDTA.
11.1. Preparation of Sucrose Solution:
11.1.1. Weigh 50 mg of EDTA and transfer to a beaker. Put about 30 ml of DDI
water and mix until dissolved.
11.1.2. Weigh 30 g of Sucrose and transfer to a 50 ml volumetric flask. Transfer
the EDTA mixture into the same flask and Q.S. to 50 ml with DDI water. Stable for 2 weeks.
12. Load the ten tubes in the small TL 100.2 rotor.
13. Centrifuge at 85,000 rpm and 5°C for 24 hours (Program 8).
14. After 24 hours (22 + or -2 hours okay), transfer the bottom half into a COBAS sample cup
labeled as “HDL” with the corresponding ID number.
14.1. With a syringe, remove 0.5 ml of the sample (HDL) from the bottom of the tube,
taking care to avoid the gel-like precipitate, and holding the syringe plunger steady while lifting it
out of the tube to prevent any mixing.
14.2 Repeat procedure 8.2 to 8.4.
15. Pour the leftover from the tube (upper half) to a COBAS sample tube labeled as “LDL” with
the corresponding ID number.
16. Store the “HDL” and “LDL” cups in the freezer together with the “VLDL” sample cups.
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HDL ANALYSIS USING PRECIPITATION METHOD

1. Number the samples you are running.
2. Number plastic microtubes (1.7 ml capacity) you will be using, accordingly.
3. Pipet 100 pi Heparin (ready to use) and 50 pi of 0.6 M MnCI2 to all the tubes.
3.1. Preparation of 0.6 M MnCI2:
3.1.1. Weigh out 11.87 g Manganese Chloride (MnCI2)
and transfer into a 100 ml volumetric flask.
3.1.2. Q.S. to 100 ml with double deionized water. Mix thoroughly.
Stable for 6 months.
4. Pipet 500 pi specimen into the tubes.
5. Close the lid of the tubes tightly and mix vigorously using Vortex mixer or any automatic
mixer.
6. Let stand for at least 1 hour at room temperature (2 hours or more if refrigerated).
6.1. Very long incubation may not give valid results.
7. Centrifuge for 15 minutes at 2,000 RPM or at maximum speed using the small Fisher
centrifuge.
8. While samples are spinning, put sample cups on COBAS sample rack with the corresponding
numbers as the samples.
9. Put about 4-5 drops of the supernatant into the sample cups using disposable transfer pipet.
9.1. Turbid supernate should be repeated using 1:1 dilution with 0.9% saline solution.
9.2. Preparation of 0.9% saline:
9.2.1. Weigh 9 g of Sodium Chloride (NaCI) and transfer into a 11 volumetric
flask.
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10. Fill up reagent bottle with HDL reagent and put in COBAS reagent rack in the
corresponding position.
10.1. Use the Cholesterol reagent (Roche) as HDL reagent.
11. Put 3-4 drops of HDL Standard (Abbott Spectrum - ready to use) and put in the
corresponding position in COBAS control rack.
11.1. There are 3 levels of HDL STD. - level 1, level 2 and level 3.
12. Load the sample and reagent racks on the COBAS machine.
12.1. See manual on how to use COBAS.
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APPENDIX G
DATA COLLECTION FORMS
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ID#

u

Week 0

WeekS

Week 16 Week 24 ID#

TC

TC

TG

TG

HDL

HDL

HDL-C

HDL-C

LDL-C

LDL-C

VLDL-C

VLDL-C

HDL-TG

HDL-TG

LDL-TG

LDL-TG

VLDL-TG

VLDL-TG

ID#

Week 0

WeekS

Week 16 Week 24 ID#

TC

TC

TG

TG

HDL

HDL

HDL-C

HDL-C

LDL-C

LDL-C

VLDL-C

VLDL-C

HDL-TG

HDL-TG

LDL-TG

LDL-TG

VLDL-TG

VLDL-TG

Data Collection Form: Lipid Panel and Lipoprotein Quantification

WeekO

Weeks

Week 16 Week 24

WeekO

WeekS

Week 16 Week 24

ID#

WeekO

Week8

Week 16

Q1B
Q2B
Q3B
Q4B
Q5B
Q1L
Q2L
Q3L
Q4L
Q5L
Q1D
Q2D
Q3D
Q4D
Q5D
Data Collection Form: Satiety and Satisfaction Questionnaire
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Week 24

ID DOB
#

Grp M/F DM

HTN W/H
0

W/H

BMI

BMI

24

0

24

u>

Cn

Data Collection Form: Demographics and body composition

fat%
0

fat%

24

fat
mass
0

fat
mass
24

FFM

FFM TBW TBW

0

24

0

24

vvt
0

vvt
24

Week

1

2

3

4

5

6

7

8

9

10

11

12

Weight

Ketone

BPs

BPd

Data Collection Form: Weekly weight, ketone and blood pressure
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14

15

16

17

18

19

20

21

22

23

24

APPENDIX H
ELIGIBILITY CRITERIA
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Eligibility Criteria
Inclusion Criteria
• Males, pre-menopausal females and post-menopausal females not receiving
hormone replacement therapy are eligible.
• Must be > 130% and < 200% of Ideal Body Weight relative to their height and
body frame according to the 1983 Metropolitan Life Insurance Company HeightWeight Table (Appendix X).
• Must undergo a complete history and physical examination performed by a
COH endocrinologist or cardiologist and have one or more of the following
medical problems: type 2 diabetes mellitus, mild to moderate HTN (treated),
mild to moderate dyslipidemia, ischemic heart disease, coronary bypass graft,
CHF, chronic obstructive pulmonary disease (COPD), and/or disabling joint
disease (DJD).
• Must undergo an electrocardiogram and 24-hour ambulatory Hotter monitoring
with measurement of QT interval and calculation of QT corrected for heart rate
and an exercise tolerance test (treadmill) to rule out evidence of active coronary
artery disease.
• Patients with a history of coronary artery disease (CAD) with chest pain and/or
dyspnea must have documented evidence of stabilization of the cardiac disorder.
• Patients who have sustained a cerebrovascular accident (CVA) and are without
active neurological symptoms are eligible.
• Patients with type 2 diabetes mellitus must be in fair to good glycemic control
with an HgbAlC level < 8.0 %.
• Must have the following baseline laboratory tests: CBC (hemoglobin,
hematocrit, white blood cell count and red blood cell indices), SMA-18
chemistry panel (glucose, sodium, potassium, chloride, total CO2, TC, blood
urea nitrogen, creatinine, uric acid, calcium, phosphorus, SCOT, SGPT, LDH,
alkaline phosphatase, bilirubin, albumin, total protein), lipid profile including
HDL-C and triglycerides, thyroxine, TSH, and complete urinalysis.
• Must have a serum creatinine <1.2 mg/dl and normal liver function. Mild to
moderate transaminase elevations (< 2x normal) at baseline are permitted.
• Must undergo a gallbladder ultrasound. Newly diagnosed gallbladder pathology
must receive medical treatment.
• Must undergo a baseline body composition evaluation using bioelectrical
impedance analyses (BIA) testing..
• Patients who require short courses of glucocorticoid medication to treat limited
inflammatory conditions are eligible.
• Must be at least 18 years of age.
• Must sign a COH approved Informed Consent and the D & CVRRP General
Information Sheet/Contract.
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Exclusion Criteria
• Undergoing treatment for malignancy.
• Current smokers.
• Self-reported allergy to almonds.
• Documented history of familial hyperlipoproteinemia with TC > 300 mg/dl, TG
> 500 mg/dl or HDL-C > 80 mg/dl.
• Recent myocardial infarction within six months of program initiation or
presence of severe HTN (diastolic blood pressure >115 mm Hg).
• Patients without a history of CAD but who have an electrocardiogram
demonstrating frequent or multifocal premature ventricular contractions,
premature atrial contractions, second degree or third degree heart block, or other
arrythmias other than a sinus arrythmia are ineligible.
• Patients with QT interval prolongations are at increased risk for ventrical
arrythmias and are ineligible.
• Evidence of active coronary artery disease found on the pre-program exercise
stress test.
• Untreated hypertension.
• Untreated hypothyroidism or hyperthyroidism, or history of total thyroidectomy
receiving total thyroid hormone replacement.
• Untreated gout or hyperuricemia. If overt gout has occurred in the past, the
study participant should be started on Allopurinol 300 mg daily prior to study
initiation.
• Documented active ulcer disease within three months of study participation.
• Documented participation in a medically supervised weight control program
within the past three months.
• No episode of phlebitis within six months of study initiation.
• Impaired renal function (creatinine >1.2 mg/dl).
• Presence of cerebrovascular disease with neurological symptoms.
• Must not have a current prednisone requirement of > 20 mg daily for more than
10 consecutive days.
• Evidence of significant psychopathology as determined by the program
psychologist, including history of active bulimia and/or anorexia nervosa.
• History of substance abuse within six months of study initiation. Patients who
are successfully treated for their addiction and have been stable for at least six
months are eligible.
• Concurrent use of anti-hyperlipidemic medications (statins), coumadin,
antidepressants, psychotropic medications (e.g. lithium), tranquilizers,
amphetamines, anti-estrogen medications (Raloxifen, Tamoxifen), hormone
replacement therapy, non-prescription vitamins, or other non-prescription
weight-reducing medications.
• Females of childbearing potential and/or pregnant women will be excluded from
the study as the effects of very low calorie diets on the fetus are unknown.
• Less than 18 years of age.
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